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The Africa Centre for Health and Population Studies has a demographic surveillance site 
200km north of Durban at the Umkhanyakude district. In this setting, blood samples are 
routinely collected and used for the diagnosis of HIV infection. In this setting and in many 
settings in Africa, samples are normally collected and stored on filter paper as dried blood 
spots (DBS) as those are easy to transport and store. DNA can be isolated/extracted from DBS 
and used for viral and/or host genomic analysis. The aim of this work was to extract DNA 
from DBS of sufficient quality and yield that could be used for subsequent analysis. 
Specifically, we aimed to perform host HLA genotyping from DBS as HLA type has an 
impact on HIV-1 replication levels.   
 
Dried blood spots were prepared from anonymous samples that are commonly used for the 
validation of new laboratory methods at the Africa Centre Virology Laboratory in Durban. 
The QIAamp DNA Mini Kit method was optimised to isolate DNA from DBS. DNA levels 
were quantified using the Qubit 2.0 Fluorometer (Qubit Assay). Polymerase chain reactions 
(PCR) were used to amplify the HLA Class 1A, 1B and 1C loci and the PCR products were 
purified using the Pure Link Purification Kit (Invitrogen Life Technologies). Sanger 
sequencing techniques were used to genotype the HLA‟s PCR products. AssignTM ATF 
Softwere v1.5 was used to detect HLA allele variations in the consensus sequences produced 
through Sanger sequencing. 
 
The DNA yield that could be extracted from the DBS was low. This was most probably due to 
the low quantity of blood that can be stored in one DBS. Despite the relatively low DNA 
yields sequencing of the target gene (HLA Class 1A, 1B and 1C) was successful using Sanger 
Sequencing and variations in the majority of the HLA alleles were detected. This MSc study 
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1.1 Human Immunodeficiency Virus (HIV) 
 
The Human immunodeficiency virus, better known as HIV-1 is a slowly replicating retrovirus 
that results in acquired immunodeficiency syndrome (AIDS). HIV infections are a global 
health problem, resulting in over 2 million AIDS-related deaths per year (Kulpa and Collins, 
2011). AIDS is a condition in humans that progressively causes failure of the immune system 
and, in turn, allows life-threatening opportunistic infections and/or cancers to thrive in the 
human body (Kassutto et al., 2004). Depending on the subtype of the virus, without treatment, 
the average survival period after infection of HIV ranges between 9 to11 years. HIV is 
transferred (between people) mainly through direct contact with infected semen, pre-ejaculate, 
vaginal fluid, breast milk, or blood. In these bodily fluids the virus is present both in free 
virus particles and within the cells of the immune system (Kassutto et al., 2004). 
 
HIV targets vital cells of the immune system such as the macrophages, dendritic cells and 
helper T cells (mainly the CD4+ T cells) (Kassutto et al., 2004). HIV infection results in 
lowered numbers of the CD4+ T cells through mechanisms such as direct viral killing of 
infected cells, killing of infected CD4+ T cells by the CD8 cytotoxic lymphocytes that keep 
an alert on infected cells within the body, and through apoptosis (programmed cell death) 
(Kassutto et al., 2004). As a result, cell-mediated immunity in the body is lost when the CD4+ 
T cell numbers decline sharply below the critical level therefore making the immune system 
prone and susceptible to infections that are opportunistic (Kassutto et al., 2004). 
 
HIV is a complex virus as seen in Figure 1.1. The viral envelope of HIV is a derivative of the 
host cell‟s plasma membrane that is obtained through a process called budding (Clapham and 
McKnight, 2002). It consists of two layers in which two types of glycoproteins are embedded; 
glycoprotein (gp)120 in the outermembrane and gp41 attached on the transmembrane 
(Engelman and Cherepanov, 2012). In order for the virus to infect a host cell it needs to attach 
to a protein found on the surface of the T cell known as CD4 and it does this with assistance 
from the two abovementioned glycoproteins. The gp120 plays a role in co-ordination of 
attachment to the host cell and gp41 is essential for the cell fusion process (Clapham and 
McKnight, 2002). These two glycoproteins work together with co-receptors on the surface of 
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the cell, chemokine receptor 5 (CCR5) or chemokine (C-X-C motif) receptor 4 (CXC4) 
(Engelman and Cherepanov, 2012; Clapham and McKnight, 2002), allowing the virus to enter 
the host cell. 
 
A viral capsid protein (p24 in Figure 1.1) is situated towards the viral core. The capsid 
surrounds the viral enzymes including the protease, reverse transcriptase, integrase and 
ribonuclease, which are all vital for HIV replication. It also houses nine genes, three of which 
(gag, pol and env) contain the information required for the production of structural proteins 
that give rise to new virus particles (Fiorentini et al., 2006). Another important HIV protein is 
the p17 matrix protein found between the viral core and the viral envelope. It is produced by 
the gag gene and serves a structural function in mature HIV particles (Fiorentini et al., 2006). 
The p17 protein lines the HIV envelope and anchors gp41 and gp120 to the envelope. p17 
also carries localisation signals which are responsible for transferring the HIV core into the 









To date the only effective treatment known for AIDS is Highly Active Anti-Retroviral 
Therapy (HAART). HAART is efficacious only in controlling the disease and complete 
eradication is yet to be achieved (Kulpa and Collins, 2011). In the past two decades, research 
has shown that the host genome plays a role in modifying disease outcome. As such, 
addressing this significant global health problem requires vast understanding on how the 
host‟s immune system responds to HIV and the mechanisms involved in viral takeover of the 
immune system in order to accelerate the development of preventative and therapeutic 
vaccines (Kulpa and Collins, 2011). 
 
1.2 Role of host genome in HIV infection 
 
While there is extensive knowledge on the genetics of HIV, there is less information on the 
role that host genome variants play in the course of HIV infection and disease progression. 
Multiple relationships occurring between specific gene variants and HIV-1 disease outcomes 
have been reported over the past 15 years (Fellay, 2009). Although most of them have not 
been confirmed or have been proven false positive, the identification of several definitive 
genotype–phenotype associations has shed new light on HIV-1 pathogenesis.  This is 
particularly true with HIV-1 where a number of host genetic factors have been determined.  
Genes that have been identified and are believed to have an effect on the progression of HIV-
1 include chemokine (C-C motif) receptor 5 (CCR5), Human leukocyte antigen B57 (HLA 
B57), Tripartite motif-containing protein 5α (TRIM5α), Apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide-like 3G (APOBEC3G) and Mannose-binding lectin 2 
(MLB2) (Fellay, 2009). 
 
1.3 Human Leukocyte Antigen (HLA) 
 
 
The HLA gene family provides instructions for making a group of related proteins known as 
the human leukocyte antigen (HLA) complex. The HLA complex helps the immune system 
distinguish the body's own proteins from proteins made by foreign invaders such as viruses 
and bacteria (Bodmer, 1987; Frahm, 2005; Goulder and Watkins, 2008). The MHC complex 
in humans consists of more than 200 genes located in the same vicinity on chromosome 6 
controlling the function of these antigens. The HLA region spans about 4 megabases of DNA 
on the short arm of chromosome 6 from 6p21.1 to p21.3 (Mehra, 2001). The class II (red), 
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class III (green) and class I (blue) genes are located from the centromeric (Cen) to the 
telomeric (Tel) end as indicated on Figure 1.2. The class I locus contains the classical genes, 
A, B and C, and the nonclassical genes E, F and G. Genes belonging to this complex are 
categorized into three basic groups: class I, class II, and class III (Figure 1.2) (Mehra, 2001).   
Humans have three main MHC class I genes, referred to as HLA-A, HLA-B, and HLA-C 
(Morandi et al., 2014). Class I antigens are cell surface glycoproteins composed of a highly 
polymorphic heavy chain (Mr 45,000) which is connected in a non-covalent manner to E2- 
micro-globulin. The heavy chain consists of 2 peptide-binding domains, an Ig-like domain, 
and a transmembrane region with a cytoplasmic tail. The heavy chain of the class I molecule 
is encoded by genes at HLA-A, HLA-B, and HLA-C loci. These molecules (Class I) are 
widely distributed with the expression of the proteins produced from them present in most, 
but not all, nucleated cell surfaces (Morandi et al., 2014). These proteins are bound to protein 
fragments (peptides) that have been exported from within the cell and brought to the cell 
surface. MHC class I proteins display these peptides to the immune system and if recognized 
as foreign (viral or bacterial peptides), the infected cells are triggered to self-destruct as a 
response to the foreign invasion.  
 
Class II antigens are composed of two glycosylated chains (Mr 32,000 and 29,000 
respectively), and are predominantly expressed by cells involved in immunological responses 
namely B cells, antigen presenting cells and activated T lymphocytes (López-Nevot et al., 
1989, Morandi et al., 2014).  There are six main MHC class II genes in humans: HLA-
DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, and HLA-DRB1. These are usually 
present exclusively on professional Ag-presenting cells (B cells, macrophages, dendritic cells, 
Langerhans cells), thymic epithelium, and activated (but not resting) T cells. Most nucleated 
cells can be induced to express class II MHC molecules by interferon (IFN)-γ. Class II MHC 
molecules consist of 2 polypeptide (α and β) chains; each chain has a peptide-binding domain, 
an Ig-like domain, and a transmembrane region with a cytoplasmic tail. Both polypeptide 
chains are encoded by genes in the HLA-DP, -DQ, or -DR region of chromosome 6.  
 
The MHC class III region of the genome encodes several molecules important in 
inflammation; they include complement components C2, C4, and factor B; tumor necrosis 
factor (TNF)-α; lymphotoxin-α; lymphotoxin-β; and three heat shock proteins. The proteins 
produced from MHC class III genes have somewhat different functions; they are involved 





Figure 1.2: Schematic drawing of the HLA locus on chromosome 6 
(http://neurowiki2012.wikispaces.com/).  
 
HLA genes have many possible variations, which leads to each person‟s immune system 
exhibiting a wide range of reactions to overcome foreign invaders, which is probably a 
likeness of the natural selective influence by historic disease outbreaks that afflicted the 
ancestors of modern human ethnic groups (O‟Brien and Nelson, 2004). Some HLA genes 
have hundreds of identified versions usually referred to as alleles, each of which is then given 
a particular number (such as HLA-B27) to identify it. Closely related alleles are thereafter 
categorized together; for example, at least 40 very similar alleles are subtypes of HLA-B27 are 
known and these subtypes are classified as HLA-B*2701 to HLA-B*2743. More than 100 
diseases have been associated with different alleles of HLA genes. For example, the HLA-
B27 allele increases the risk of developing an inflammatory joint disease called ankylosing 
spondylitis (Klein and Sato, 2000). Many other disorders involving abnormal immune 
function and some forms of cancer have also been associated with specific HLA alleles. The 
abundant variation in HLA alleles provides a broad range for individual recognition of virus 
agents to which they had been exposed in the past, as well as those to which they had not 





1.3.1 Role of the HLA Class I in HIV-1 infection/progression 
 
In previous research it has been concluded that HIV-specific CD8+ T cells play a central role 
in the primary amount of the virus found in the blood and the long-term suppression of viral 
replication (Leslie et al., 2010). This conclusion is supported by the observed correlation 
between possession of particular human leukocyte antigen (HLA) class I alleles and the 
control of HIV, measured mainly in two ways, both directly by time-to-AIDS and indirectly 
via clinical markers of disease progression such as viral load (VL) and CD4 count. Specific 
HLA class I alleles have been shown to be allied with satisfactory successful control of viral 
replication and in slowing down disease progression, with alleles such as HLA-B*57 and 
HLA-B*27 showing the most noticeable results. Some alleles however, such as B*35(Px), 
B*5802, and B*18, have demonstrated the opposite effect showing relatively ineffective 
control of viral replication and instead rapidly progressing the disease (Leslie et al., 2010). In 
addition, certain trends have also been described indicating a HLA class I heterozygote 
advantage such as B*3910-Cw*1203 and B*8101-Cw*0401 (Leslie et al., 2010). 
Associations with lower VL and higher CD4 count can only be observed when the two alleles 
(B*8101-Cw*0401) are expressed together; in the absence of either of the two their protective 
quality is lost. In the case of B*3910-Cw*1203, B*3910 is only protective when associated 
with Cw*1203. It is still however, not clear whether this information demonstrates a benefit 
of Cw*1203 or of the haplotype as a whole (Leslie et al., 2010).  
 
Detectable HIV- specific CD8+ T-cell responses amongst different HLA class I loci, 
responses that express a more effective “poly-functional” phenotype, CD8+ T cells that exert 
the strongest selection pressure on the virus and the strongest HLA association with both slow 
and rapid progresssion are a few disease outcomes that can be associated with the HLA-B 
alleles. This, therefore, has led to the opinion that CD8+ T-cell responses restricted by HLA-
B alleles play a dominant role in most influential disease outcomes associated with HIV 
(Leslie et al., 2010). 
The HLA-B allele most consistently associated with potent control of HIV-1 is B57, with 
B5701 observed almost exclusively in the Northern Hemisphere and B5703 mostly in African 
ancestry. HLA B57 is a HLA-B serotype, the sister serotype of B58. According to a study 
conducted by Descours et al. (2012), HLA B57 plays a large role in depressing the size of the 
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HIV reservoirs and also in the distribution of HIV by preserving the central memory cells 
(TCM) compartment but at the same time not affecting other CD4 T-cell subsets. To determine 
whether these protective HLA alleles could impact the cell HIV-DNA distribution in resting 
CD4 T-cell subsets, 18 long-term non-progressors (LTNPs) from the LTNP cohort, which 
included 8 HLA-B27/B57–positive and 10 non–HLA-B27/B57 LTNPs were analysed 
(Descours et al., 2012). No significant differences were reflected of pVL or CCR5 expression 
due to this preservation, but instead a robust CD8 T-cell response against HIV Gag observed 
in HLA-B27/HLA-B57 LTNPs was seen (Descours et al., 2012). This could be explained by 
the fact that heterozygosity for human leukocyte antigen genes of class 1 loci (A, B, and C) 
have been shown to be associated with delayed disease progression to AIDS in HIV infected 
individuals while homozygosity of these loci has been associated with rapid progression to 
AIDS eventually leading to death (Descours et al., 2012). The advantage in being 
heterozygous is most likely because individuals with such loci for HLA are able to produce 
higher numbers of antigenic epitopes to cytotoxic T-lymphocytes than homozygotes, resulting 
in a stronger and more effective immune response when conquering HIV-1 infection. 
 
In another study to further investigate the association between HLA type and the control it has 
on HIV, Leslie et al. (2010) used a cohort comprising 1211 subjects from Durban (South 
Africa) that were chronically infected with the HIV C-clade and were treatment-naïve. 
The aim of the study was to determine whether polymorphisms in HLA-A and HLA-C can 
indeed influence disease progression or whether results are due to the dominant role that 
HLA-B is said to have on the progression of the disease (Leslie et al., 2010).  
Variations in viral load (VL) in the cohort were measured using the nonparametric Kruskal-
Wallis test of variance. This test does not only assess significance but also produces a 
Kruskal-Wallis statistic, H, which corresponds to the strength of the effect being tested. The 
effect tested was the differential contribution that the different HLA types (A, B and C) have 
on the variation in VL by grouping the individuals according to HLA type. They first grouped 
individuals by their HLA-A type and repeated the test, grouping individuals in turn by their 
HLA-B and HLA-C types. Comparisons of the VLs in subjects expressing the relevant allele 
with VLs in subjects not expressing that allele was the key concept used in analyzing HLA 
type associations with VL. This analysis was undertaken for a total of 65 alleles using the 
stringent Boneferroni correction, a method used to neutralize the problem of multiple 
comparisons, generating significance cut off P value of <0.0007. Associations between HLA 
class 1 types and the absolute CD4 count were assessed following the same steps as stated 
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above. The results showed that the HLA-B type was the strongest predictor of both VL and 
CD4 while HLA-A type was the weakest predictor of the three. 
They further examined the possibility that the observed dominant effect of HLA-B on VL and 
CD4 count might be a coincidence of the fact that the main protective (B*57 and B*5801) and 
susceptible (B*5802 and B*18) alleles happen to belong to the HLA-B locus. Initially, all 
subjects possessing B*57, B*5801, B*5802, and B*18 from the data set were excluded and 
they repeated the analysis on the remaining 682 subjects. Even with these four alleles 
excluded, HLA-B remained the strongest predictor of both VL and CD4 while HLA-A type 
remained the weakest. A more sophisticated likelihood ratio test (LRT) was implemented to 
confirm this observation. This ratio works by allowing the top four alleles described above to 
be used as covariates instead of disregarding them from the analysis. The method also 
identified HLA-B as the strongest predictor of both VL and CD4 count as when all alleles 
were considered.  
Taken together, these data suggest, firstly, that the dominant role of HLA-B in controlling 
HIV infection extends beyond the strongest four HLA-B associations and, secondly, that 
much of the apparent impact of HLA-A alleles on VL is related to linkage disequilibrium with 
HLA-B alleles, as grouping by HLA-A type no longer significantly explains any variation in 
VL or CD4 count when the top four HLA-B alleles are either excluded or used as covariates. 
Whether this apparent association between HIV immune control and HLA-B is a general and 
a causal trend or, rather, is biased by the coincidence that the strongest HLA associations with 
either extreme of disease control happen, by chance, to involve HLA-B alleles still remains 
uncertain as other studies state otherwise (Leslie et al., 2010). More downstream analysis of 
the gene need to be done in order to settle the uncertainty around it. 
Stephens (2005) states that in the African, Caucasoid and Asian population HIV-1 is 
diversifying at a fast rate. This diversity is believed to run in parallel with the extensive 
polymorphism that is displayed by genes encoding HLA class I (Stephens, 2005). Imprinted 
mutations in HIV-1 mediated by immune responses linked to the HLA class I molecules 
affect HIV-1 diversity. Many studies based on intra- and inter-ethnic populations have shown 
reproducible HLA class I allele, haplotype and supertype links with HIV-1 infection and also 
with the development of AIDS  (Stephens, 2005). It is therefore essential for this host gene 
(HLA class 1) to be analyzed so its role in the manner of development of the disease can be 
understood, predict risk and be used to personalize care.  
McLaren et al. (2015) tested for associations with set point viral load in approximately 8 
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million variants. These variants included single nucleotide polymorphisms (SNPs), short 
insertions and deletions, usual HLA alleles, and variable amino acids in HLA proteins of the 
European ancestry that consisted of 6315 individuals. They did this by combining the 
majority of available genome-wide genotyping data in HIV-infected populations with clinical 
data as they believed that previous genome-wide association studies based on similar 
populations were underpowered to detect common variants with moderate impact on disease 
outcome and had not considered the phenotypic variance which can be explained by additive 
effects of genome–wide variation (McLaren et al., 2015). Their main aim in the study was to 
map the genomic regions with the greatest influence on the viral load of HIV and quantify the 
impact those regions have. The results revealed that 14.5% of the observed variations in the 
HIV-1 viral load were explained by the SNPs in the chemokine (C-C motif) receptor 5 better 
known as CCR-5 and by the amino acid positions located in the HLA proteins binding 
grooves specifically HLA-A and HLA-B. Additional to this, an estimated 5.5% of the 
variations were explained by additive genetic variation. This, therefore, validated that the 
majority of the host genetic components playing role in managing the HIV viral load are 
explained by common variants of large effect (McLaren et al., 2015). 
 
It is important to note that the major obstacle in performing genomic studies is the 
requirement of a large amount of blood that is repeatedly needed from sample subjects of 
experiments or studies to extract the DNA from white blood cells (Zhou et al., 2006). 
Fortunately, the reawakening of a method of sampling, in existence for a number of years, 
known as dried blood spots (DBS), has regularized the storage of blood for these studies. 
DBS require only a small amount of blood from the subjects and these blood samples can be 
stored for a number of years (Hue et al., 2011; St. Julien et al., 2013).  
 
1.4 Dried Blood Spots 
 
Dried blood spots (DBS) refers to a blood sampling technique where small volumes of blood 
are spotted on an appropriate filter paper, dried, and taken to the laboratory for analysis 
(Figure 1.3). Collection of blood samples on filter paper can be dated to more than 40 years 
ago (Hue et al., 2012; Jahannessen, 2010).  This simple and practicable collection and storage 
method has been adopted for broad use in analytical screening, drug monitoring, and genetic 
analysis, being particularly suitable for molecular epidemiologic studies in remote areas with 
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tropical climate, where transport and storage conditions are often not the most favorable 
(Chaisomchit et al., 2003; Chaisomchit et al., 2005). Most samples are stable at room 
temperature when dried on these filter papers for at least a week, thereby obviating the need 
for maintaining a cold chain for transportation of the sample (Lakshymy, 2008).  
 
Archived dried blood spots are an important and precious resource for genomic research. 
Unlike venipuncture, the technique is minimally invasive (Lakshymy, 2008) and there is no 
need for centrifugation and separation of samples, making dried blood suitable for field 
applications with minimum involvement of laboratory-trained laborers (Lakshymy, 2008). In 
addition, it is also inexpensive and easy to analyse and automate. DBS samples are 
compatible with a large number of bio-analytical methods, among them chromatography, 
mass spectrometry, DNA fingerprinting, and immunoassays (Chaisomchit et al., 2005). DNA 
in the filter paper is entrapped into a chemically treated matrix that avoids degradation, and 
ambient storage is possible for years without deterioration (Pachot et al., 2007). Considering 
the growing knowledge of genetic polymorphisms that might be implicated in the 
pathogenesis of major diseases such as HIV-1 and AIDS, the advantages of DBS samples 
may facilitate polymorphism analysis in routine clinical practice and the creation of large 








Polymerase chain reaction (PCR) is a requirement for amplification of the desired genes 
(Zhou et al., 2006). Over the years a shortfall has been reported in PCR results when DBS are 
used as the source of genomic DNA. This could likely be the consequence of low purity, 
stability, and integrity of the extracted genomic DNA from filter paper. Analysis of blood 
spots poses few challenges, mainly that of elution of red blood cells along with the analyte of 
interest (Lakshymy, 2008). This is due to cellular components rupturing when whole blood 
samples are dried on filter, which further decomposes into solutions when blood spots are 
reconstituted leading to additional extraction procedures being required for certain analytes to 
overcome this problem (Lakshymy, 2008).  The majority of PCR inhibitors are integrated 
from the sample or introduced while samples are being processed or in nucleic acid 
extractions. Examples of known blood components that become problematic in PCR 
amplification are namely immunoglobin G, haemoglobin and lactoferrin (Al-Soud and 
Radstrom, 2000). These components reduce the amplification efficiency by decreasing 
sensitivity of the procedure or by giving false-negative results (Schrader et al., 2012, Al-Soud 
and Radstrom, 2000). They do so by binding to the DNA polymerase, which in turn prevents 
the assembling of nucleotides to form DNA strands (Al-Soud and Radstrom, 2000). 
 
Another key problem with sample collection on filter paper is the efficiency of elution of the 
analyte of interest and relative sample volume limitations of sample collected that can be 
incorporated into the extraction procedure (Wong et al., 2008; Lakshymy, 2008). Therefore, 
an efficient method for recovering high quality genomic DNA from dried blood specimens is 
required. There are many commercially available kits for extracting DNA from dried blood 
samples such QIAGEN kits but the problem with these is that they are expensive and involve 
spin columns that provide low recovery rates. Furthermore, the spin column kits used in these 
kits always result in increased plastic waste demonstrating undesirability of this extractive 
process (Chaisomchit et al., 2003; Lin et al., 2005).  
 
1.4.1 DNA extraction from Dried Blood Spots 
 
Despite the known drawbacks, storage of blood as dried spots on filter paper is a practicable 
approach for genetic screening (Sirdah, 2014; Lakshymy, 2008). A number of DNA 
extraction kits have been available commercially for many years, but do not accommodate the 
use of DBS in their extraction protocols. Newer kits such as QIAamp DNA mini and 
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microkits can now be used to extract DNA from DBS (Sirdah, 2014). Automated DNA 
extraction methods have also been discovered that accommodate extraction of DNA from this 
sample type such as the automated liquid handling system that purifies DNA from FTA cards 
(Sirdah, 2014) and a DNA extraction method using the MagNA Pure LC, a magnetic particle 
based automated extraction discussed in de Vries et al. (2009). 
 
Table 1.1 is a summary of different extraction methods described by numerous authors 
alleged to produce good quality DNA from DBS.  Modifications have been implemented in 
some of these extraction methods with a purpose of increasing the DNA quality and yield 
they produce. The table also shows the different technologies that these authors used to 
validate the quality and purity of the extracted DNA samples. 
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Table 1.1: Results obtained from various publications based on the extraction of DNA from DBS using different extraction methods and 
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Method 2  
(1 extraction 
step) 












Lin et al., 2005  
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1.5 DNA Sequencing 
 
DNA sequencing is the process used for determining the specific order of nucleotides within 
a DNA molecule.  Any method or technology that can be utilized to determine the order of the 
four bases (adenine, guanine, cytosine, and thymine) in a strand of DNA is referred to as 
DNA sequencing (França et al., 2002). Applied fields such as biotechnology, virology, 
medical diagnosis, medicine and biology rely greatly on DNA sequencing, and the high speed 
of sequencing has been influential to the sequencing of complete DNA sequences and 
genomes of numerous types of species of life such as the human genome (França et al., 2002). 
The first DNA sequences were obtained in the early 1970s by academic researchers, Hamilton 
Smith and his coworkers, using laborious methods based on two-dimensional chromatography 
(Smith and Welcox, 1970). They discovered type II restriction enzymes, which can recognize 
and digest DNA at specific nucleotide sequences and making it possible to cut a large DNA 
fragment into numerous smaller pieces that could be separated according to their sizes by 
using gel electrophoresis (Smith and Welcox, 1970). 
 
1.5.1 Sanger Sequencing 
 
The classical chain-termination method, commonly referred to as Sanger sequencing, is a 
DNA sequencing method that requires a single-stranded DNA template, a DNA primer, DNA 
polymerase, normal deoxynucleosidetriphosphates (dNTPs), and modified di-
deoxynucleosidetriphosphates (ddNTPs). The ddNTPs are responsible for the termination of 
the DNA strand elongation (Sanger et al., 1977; Karger and Guttman, 2009). These chain-
terminating nucleotides lack a 3'-OH group required for the formation of a phosphodiester 
bond between two nucleotides, causing DNA polymerase to terminate extension of DNA 
when a modified ddNTP is integrated into a DNA strand. The resulting newly synthesized 
DNA chains will be a mixture of lengths, depending on how long the chain was when a 
ddNTP was randomly integrated into the chain. The ddNTPs may be radioactively 
or fluorescently labeled for detection in automated sequencing machines (Sanger et al., 1977; 




The DNA sample is divided into four separate sequencing reactions, containing all four of the 
standard deoxynucleotides (dATP, dGTP, dCTP and dTTP) and the DNA polymerase.  To 
each reaction, only one of the four dideoxynucleotides (ddATP, ddGTP, ddCTP, or ddTTP) is 
added while the four other nucleotides are standard ones. To put it in a more sensible order, 
four separate reactions are needed in this process to test all four ddNTPs (França et al., 2002; 
Karger and Guttman, 2009). Following rounds of template DNA extension from the bound 
primer, the resulting DNA fragments are heat denatured and separated by size using gel 
electrophoresis and visualized by autoradiography or UV light reading them directly off X-ray 
film or gel image (Sanger et al., 1977; França et al., 2002; Karger and Guttman, 2009). 
 
1.5.2 Sanger sequencing with capillary electrophoresis 
 
The aftermath of the discovery of Sanger sequencing, saw Smith and his associates, 
introducing a dye-terminator alternative that is less time consuming than the original chain-
terminator.  In this method, the same principle as chain-termination though different size 
fluorescent DNA fragments are generated by incorporation of dye-labeled ddNTPs is used 
(Smith et al., 1986). Each of the four ddNTP chain terminators are integrated with a different 
fluorescent dye, allowing sequencing in one reaction rather than four (Figure 1.4). When 
DNA template, unlabeled primer, dNTPs, four fluorescently labeled ddNTPs and DNA 
polymerase are mixed together, different size fluorescent DNA fragments are generated by 






Figure 1.4: Diagram showing the process followed in Sanger sequencing when using dye-
terminators (http://www.scq.ubc.ca/wp-content/uploads/2006/08/sequencing2.gif). 
 
A breakthrough in DNA sequencing technology was demonstrated when viewing a sequence 
on the slab gel was replaced by viewing using capillary electrophoresis. Prior to this, the 
DNA sequencing products were separated using polyacrylamide gels, manually poured 
between two glass plates that was a tedious process.  In capillary electrophoresis, the DNA 
sequencing products enter the capillary as a result of an electrokinetic injection (Drossman et 
al., 1990). In essence, a high voltage charge is applied to the sequencing reaction buffer and 
the voltage in turn pushes the negatively charged fragments into the capillaries leading to the 
DNA sequencing products being separated by size based on their total charge (Drossman et 
al., 1990). These detect and record dye fluorescence, and output the data as fluorescent peak 
trace chromatograms. Sequencing reactions (thermocycling and dye-labelling), cleanup and 
re-suspension of samples in a buffer solution are performed separately, before loading 
samples onto the sequencer. Sanger sequencing with obtainable sequence length 1000 bps 
using dye-terminators thereafter became the dominant sequencing technique until the 
introduction of so-called next-generation sequencing technologies (Drossman et al., 1990). 
 
1.6 Aim and objectives  
 
A significant increase in understanding host genetic and genomic determinants of 
susceptibility to HIV-1 infection and disease progression has been witnessed over recent years 
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mainly through identifying common variants in some host loci that influence disease 
progression, characterizing the scale and dynamics of gene and protein expression changes in 
response to infection and lastly providing pathways involved in in viral replication through 
comprehensive catalogs of genes (Telenti and Johnson, 2012). Candidate gene studies, 
genome-wide association studies, genome-wide transcriptome analyses, and large-scale in 
vitro genome screens mainly drive these discoveries (Telenti and Johnson, 2012). 
 
As asserted in Lakshymy (2008) storing blood as dried blood spots is a powerful tool in 
screening programs and especially research based on a large population. This is because it is a 
method of blood collection that is less invasive and relatively painless, which gives it an 
advantage over other methods especially when working with elderly people or infants. Blood 
stored in this manner can also be transported without a cold chain which makes it suitable for 
research on developing countries where facilities are far from cohorts being studied and 
where cost is a major issue hindering the progress of research (Lakshymy, 2008). 
 
It is imperative that DNA extraction methods producing good quality DNA with high yields 
from DBS are discovered for deeper understanding of susceptibility to HIV-1 infection and 
disease progression. The aim of this MSc research project is to produce high yield and good 




Extract DNA of good quality and high yield from dried blood spots. 
 
Objective 2 
Amplify HLA Class 1A, 1B and 1C loci using nested PCR 
 
Objective 3 
Sequence PCR products 
 




2. MATERIALS AND METHODS 
 
2.1 Dried blood spots 
 
Dry blood spots (DBS) were prepared from anonymous blood samples that are commonly 
used for the validation of new laboratory methods at the Africa Centre Lab in Durban. 50 Pl 
of the blood sample were pipetted onto each circle on a filter paper card (Whatman 903TM, 
UK) and the filter cards were allowed to dry at room temperature for 3 hours in a sterile 
environment (laminar airflow). Thereafter, the cards were placed in an envelope with a packet 
of dessicant and the envelope was placed in a zip lock bag before storing in an airtight 
container at -20qC.  
 
2.2 DNA Extraction 
 
Two DNA extraction methods, QIAamp® DNA Mini Kit (QIAGEN, Germany) and 
PrepFiler® Forensic DNA extraction Kit (Life Technologies, California) were used to 
determine which of the two would give the best quality and yield of DNA (summarized in 
Appendix A.1). The QIAamp® DNA Mini Kit was shown to generate best yields and is 
described below. 
 
DNA from the DBS was extracted using QIAamp® DNA Mini Kit according to the 
manufacturer‟s instructions with a few modifications (as indicated below). The protocol was 
optimized in attempt to isolate good quality DNA from the samples. The following procedure 
was followed: 
 
A metal one-hole paper punch was used to punch out two 3 mm circles from a dried blood 
spot. These were placed into a 1.5 ml microcentrifuge tube with 180 μl of Buffer ATL. The 
microcentrifuge tube was incubated at 85°C for 10 min in a shaking heating block (Eppendorf 
Thermomixer compact) and briefly centrifuged (Eppendorf 5415 R centrifuge). 20 μl 
Proteinase K was added to the microcentrifuge tube and mixed by vortexing using a FINE 
VORTEX (FINE PCR) at full speed, before incubation at 56°C for 60 min in a stationary 
heating block (TECHNE DRI-Block DB.2A). The tube was briefly centrifuged to collect the 
fluid at the bottom of the tube.  200 μl of Buffer AL was then added to the sample, mixed 
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thoroughly by vortexing at high speed, and incubated at 70°C for 10 min in a stationary 
heating block. All fluid was collected by brief centrifugation. The cell lysate was then passed 
through a QIAshredder (QIAGEN) at full speed for 2 min in an Eppendorf 5415 R centrifuge. 
The QIAshredder column was discarded and the collection tube containing the DNA and the 
lysate was retained. 
 
200 μl of 100% ethanol was added to the lysate and mixed thoroughly by vortexing at high 
speed. The mixture was carefully applied to the QIAamp Spin Column (in a 2 ml collection 
tube) and centrifuged at 6000 x g for 1 min. The QIAamp Spin Column was then transferred 
into a clean 2 ml collection tube. 500 μl of Buffer AW1 was added to the spin column and the 
tube centrifuged at 6000 x g for 1 min. The filtrate was discarded and the collection tube 
replaced. Thereafter, 500 μl of Buffer AW2 was added to the spin column and centrifuged at 
full speed for 3 min. To eliminate any chance of Buffer AW2 carryover, the QIAamp Spin 
Column was transferred into a clean 2 ml collection tube and centrifuged at 20 000 x g for 1 
min to dry the membrane. DNA was eluted by adding 100 μl Buffer AE to the QIAamp Spin 
Column placed in a clean 1.5 ml microcentrifuge. The sample was incubated at room 
temperature for 1 min before centrifugation at 6000 x g for 2 min. All extracted samples were 
stored in at -80qC. 
 
2.3 DNA quantification 
 
DNA concentrations of the extracted samples were quantified using the Qubit 2.0 
Fluorometer (Qubit Assay). The extracted samples were also separated on a 1% agarose gel at 
70V using a Bio-Rad Powerpac (Basic) for 45 min in 1x TBE buffer. For the purpose of DNA 
illumination under a UV light source 1 Pl of Novel juice (Gene Direx) was mixed with 4 Pl of 
the PCR product before running the gel. The gel was imaged using a GelDocTM XR+ imaging 
system (Bio-Rad) and Image Lab 4.1 software package (Bio-Rad). This was done to confirm 
the presence of DNA particularly in the samples that had given invalid concentrations as seen 






2.4 Polymerase chain reactions 
  
Numerous attempts at the nested polymerase chain reaction (PCR) were conducted to find the 
most appropriate and conducive PCR conditions that amplified the expected product size 
(approximately 1000 bp) for the HLA Class 1A, 1B and 1C loci (summarized in Appendix 
C.1 and C.2). The KAPPA2GTM Robust HotStart ReadyMix 2X (KAPABIOSYSTEMS) kit 
was used to amplify the PCR product. PCR amplifications were performed using the Gene 
Amp PCR System 9700. A total of 12 samples underwent amplification; 10 samples from the 
anonymous donors, an HIV negative blood sample used as a positive control (+ve) and 
deionized water used as a negative control (-ve) as seen in Figure 3.2. 
 
2.4.1 PCR Step 1 
 
The nested polymerase chain reaction involves two sets of primers, used in two successive 
runs of PCR, the second set intended to amplify a secondary target within the first run 
product. It is done in this manner to attempt eliminating the commonly occurring problem of 
primers binding to incorrect regions of the DNA, giving unexpected products. 
 












 5’                                                                          3’ 
Primer size 
A   5A.1 CCC AGA CGC CGA GGA TGR CSG 21 bases 
  3A1.1 GCA GGG CGG AAC CTC AGA GTC ACT CTC T 28 bases 
B   5B.1 TCC CAG TTC TAA AGT CCC CAC G 22 bases 
  3B.1 TCC ATT CAA GGG AGG GCG AC 20 bases 
C   5C.1-2 AGC GAG GKG CCC KCC CGG CGA 21 bases 
  3C.1-2 GGA GAT RGG GAA GGC TCC CCA CT 23 bases 
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As mentioned above the second set of primers are intended to amplify a secondary target in 
the first run, therefore 2,5 Pl of the PCR product in step 1 was used as the sample in step 2 of 









Reagents Volume / reaction 
(Pl) 
Water  3.8 
Master Mix 10 
MgCl2  (25mM) 0.4 
Primer 1(10uM) 0.4 
Primer 2 (10uM) 0.4 
Sample  5 
Total reaction volume 20 
Thermocycling Conditions 
(Step 1) 
Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 63 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 
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2.4.2 PCR Step 2 
 
Table 2.4: Primer sequences used to amplify HLA Class 1A, 1B and 1C loci in step 2 of the 
nested PCR. 
 
Table 2.5: Reagent volumes used for PCR amplification in step 2 of the nested PCR. 
 
Reagents Volume / reaction 
(Pl) 
Water  7.5 
Master Mix 12.5 
Enhancer 1.0 
MgCl2 (25mM) 0.5 
Primer 1(10uM) 0.5 
Primer 2 (10uM) 0.5 
Sample  2.5 
Total reaction volume 25 
 












  Primer   
name 
Primer sequence 
5’                                                                          3’ 
Primer size 
A   5A1N1 CCT CTG YGG GGA GAA GCA A 19 bases 
  3A1N3 GAC TCA GAA GTG CTG CTG GAC TC 23 bases 
B 5B3 GGC TCC CAG TTC TAA AGT CCC CAC G 25 bases 
  3B1 CCA TCC CCG GCG ACC TAT AGG AGA TG 27 bases 
C CEX1F-2 CCT GAY CGA GAC CTG GGC C 19 bases 
  DMEX3 TGG GAG GCC ATS CCG GGA GAT 21 bases 
Thermocycling Conditions 
(Step 2) 
Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 65 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 
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PCR products of step 2 were subjected to gel electrophoresis to determine whether the 
expected product size (1000 bp) had been amplified. 
 
2.5 Gel electrophoresis 
 
PCR products were examined by gel electrophoresis in a 1% agarose gel run at 70V with a 
Bio-Rad Powerpac (Basic) for 45 min in 1x TBE buffer. 200bp O‟RangeRulerTM DNA ladder 
(Thermo Scientific) was used to determine product size. For the purpose of DNA illumination 
under a UV light source 2 Pl of Novel juice was mixed with 2 Pl of the DNA ladder and 1 Pl 
of Novel juice mixed with 4 Pl of the PCR product before running the gel. The gel was 
imaged using a GelDocTM XR+ imaging system (Bio-Rad) and Image Lab 4.1 software 
package (Bio-Rad).  
 
2.6 PCR product purification 
 
PCR products were purified using the Pure Link Purification Kit (Invitrogen Life 
Technologies) following the manufacturer‟s protocol.  
 
Briefly, 4 volumes of PureLink® Binding Buffer (B2) were added to 1 volume of the PCR 
product and mixed by vortexing. The samples were thereafter transferred into a PureLink® 
Spin Column in a collection tube. An amount of 650 μl of Wash Buffer was added to each 
column. The columns were centrifuged at 10 000 x g for 1 min at room temperature.  The 
flow through was discarded and the spin column placed into a new collection tube. It was 
centrifuged at maximum speed for 3 min at room temperature.  The spin column was then 
placed in a clean 1.7 ml PureLink® Elution Tube. The PCR products were eluted by adding 
50 μl of elution buffer (10 mM Tris-HCl, pH 8.5) into the center of the spin column. The 
column was incubated at room temperature for 1 min before centrifuging at maximum speed 







2.7.1 Sequencing reaction 
 
The PCR products were sequenced using the ABI Prism BigDye Terminator kit v3.1 Cycle 
Sequencing Kit (USA) and 4 primers for each sample.  
 
Table 2.7: Primer sequences used to generate the four fragments of the HLA Class 1A, 1B 









INT2R GGA TCT CGG ACC CGG AG (exon 2) 
A1N110 AGC CGC GCC KGG AGG AGG GTC G (exon 2) 
5AE3.2 GTT TAG GCC AAA AAT YCC CC (exon 3) 




INT2R GGA TCT CGG ACC CGG AG (exon 2) 
3B1 TCC ATT CAA GGG AGG GCG AC (exon 2) 
5BE2.2 GGG AGG AGM GAG GGG ACC SCA G (exon 3) 




INT2C CGA CCC GGG CCG TC (exon 2) 
BC3N1P3 GGC TCC CCA CTG CCC CTG GTA C (exon 2) 
5CE2.2 GGC TCC CCA CTG CCC CTG GTA C  (exon 3) 
3CE3.2 AGA TGG GGA AGG CTC CCC ACT (exon 3) 
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The amplification reaction consisted of 5.1 Pl water, 0.4 Pl Ready Reaction mix, 0.5 Pl 
primer (5PM) (as seen in Table 2.7), 2 Pl 5X sequencing buffer and 2 Pl of the template (20 
pmol/μl) making a total volume of 10 Pl for each primer. PCR was performed using the Gene 
Amp PCR System 9700. The thermal cycles were programmed as follows:  
 
Figure 2.1: Programmed thermal cycles used for the sequencing reaction (Adapted from 
Manasa et al., 2014). 
 
2.7.2 Sequencing cleanup 
 
The sequences were immediately cleaned after PCR amplification following the SATuRN/ 
Life Technologies Genotyping Manual procedure (ABI).  
 
Table 2.8: The volumes of each reagent used in preparing fresh sodium acetate and ethanol 
for sequence cleanup. 
 
 
Reagent X1 (Pl) X120 (for on full plate) 
3M sodium acetate 5 240 
100% EtOH 50 6000 
Total 55 6240 
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55 Pl of sodium acetate solution (Table 2.8) was added to each well. The wells were then 
carefully sealed with an adhesive foil cover and mixed by vortexing at high speed. Thereafter, 
the samples were centrifuged at 3000 x g for 20 min. The foil cover was then removed and the 
plate was inverted onto a folded „kimwipe‟ to remove supernatant but cautiously enough not 
to dislodge the pellet. For further drying, the plate was centrifuged while still inverted on 
„kimwipes‟ at 150 x g for 2 min.  150Pl of 70% ice cold EtOH was immediately added to 
each well, it is vital that the addition of EtOH is immediate, as dye blobs will form if there is 
any delay. The samples were centrifuged at 3000 x g for 5 min and thereafter the plate was 
inverted over folded „kimwipes‟ followed by centrifugation at 150 x g for 1 min still inverted. 
The uncovered plate was then dried at 50qC for 5 min in a thermocycler and, once dry, the 
plate was thereafter reconstituted with 10μl of formamide and denatured at 95°C for 2 min 





Geneious R8 v8.1.8 was used to edit and map the four sequences from Sanger sequencing into 
a consensus sequence. The reads were mapped into a consensus sequence using the de novo 
assembly option. The PubMed NCBI BLAST (Basic Local Alignment Search Tool) was used 
to align these new sequences. They were aligned against the non redundant (NR) database for 
sequence quality control purposes. This was done in order to evaluate if the consensus 
sequences fall under the HLA Class 1 loci. The AssignTM ATF Softwere v1.5 (Conexio 
Genomics, Australia) was also used to detect variation of HLA Class 1A, 1B and 1C alleles in 
the reads of the 10 sequenced samples. 
 
2.8.1 Sequence Quality control 
 
Reads produced from Sanger sequencing were edited using Geneious R8 v8.1.8. Normally the 
first 30-50 bp and the last 100-200 bp of sequence reads are of low quality and are therefore 
trimmed off leaving only the section of the reads that are of good quality (as seen in Figure 






Figure 2.2: Image showing a read obtained from Sanger sequencing being edited by trimming 
off the ends, which are of bad quality. Bases from no. 62 to 925 form the section of the read 
that will be used in the analysis of interest (http://www.geneious.com). 
 
The tables that follow (Table 2.9 to Table 2.11) shows all the primer reads that underwent 
trimming in order to extract the section of the reads that were of good quality. The tables 
show the length (bp), quality (%) and GC content (%) present in these reads before and after 















Table 2.9: Quality and length of HLA Class 1A Sanger sequencing reads before and after 
















Primer sequence Before Editing  After Editing 
Length (bp) Quality (%) GC conc. (%) Length (bp) Quality (%) GC conc. (%) 
HLA1_Class 1A_INT2R 828 54.3 70.7 569 79.1 70.8 
HLA1_Class 1A_A1N110 1111 55.4 66.4 912 67.3 66.6 
HLA1_Class 1A_5AE3.2 793 78.4 61.7 663 93.5 61.5 
HLA1_Class 1A_3AE3.2 1096 65.3 68.9 880 81.3 68.9 
HLA2_Class 1A_INT2R 1181 35.9 68.8 608 68.8 70.2 
HLA2_Class 1A_A1N110 1107 51.9 67.7 886 63.1 68.2 
HLA2_Class 1A_5AE3.2 1032 41.2 62.6 719 58.7 62.6 
HLA2_Class 1A_3AE3.2 1111 58.4 69 887 72.3 69 
HLA3_Class 1A_INT2R 752 50.5 69.8 509 73.1 69.9 
HLA3_Class 1A_A1N110 1111 47 65.3 942 55.4 65.9 
HLA3_Class 1A_5AE3.2 697 62.1 61.3 573 75.4 61.3 
HLA3_Class 1A_3AE3.2 1101 52.3 67.2 858 67 67.2 
HLA4_Class 1A_INT2R 927 42.0 70.5 718 56.5 70.5 
HLA4_Class 1A_A1N110 1098 54.5 67.9 780 74.6 67.9 
HLA4_Class 1A_5AE3.2 1110 50.5 60.2 649 86 60.2 
HLA4_Class 1A_3AE3.2 1148 59.8 68.7 891 76.8 68.5 
HLA5_Class 1A_INT2R 716 47.2 69.3 492 67.9 69.3 
HLA5_Class 1A_A1N110 1095 52.6 67.3 888 64.2 67.3 
HLA5_Class 1A_5AE3.2 685 76.8 61.4 643 81.2 61.3 
HLA5_Class 1A_3AE3.2 1088 59.7 68.8 861 74.7 68.8 
HLA6_Class 1A_INT2R 992 32.2 67.6 481 63.2 67.6 
HLA6_Class 1A_A1N110 1080 51.3 66 835 63.4 66.7 
HLA6_Class 1A_5AE3.2 859 40.7 62 685 50.9 62 
HLA6_Class 1A_3AE3.2 819 67.6 68.3 769 71.8 68.3 
HLA7_Class 1A_INT2R 825 53.9 70.4 563 78.7 70.3 
HLA7_Class 1A_A1N110 1087 42.5 66.3 846 54.1 67 
HLA7_Class 1A_5AE3.2 697 52.4 65.7 435 81.1 65.7 
HLA7_Class 1A_3AE3.2 1113 59.7 68.1 842 77.4 68.1 
HLA8_Class 1A_INT2R 655 65.2 70.2 521 77.4 70.2 
HLA8_Class 1A_A1N110 1110 50.4 67.2 725 72.1 67.2 
HLA8_Class 1A_5AE3.2 699 62.8 61 554 77.4 61.0 
HLA8_Class 1A_3AE3.2 1134 53.5 67.8 832 70.6 67.8 
HLA9_Class 1A_INT2R 1114 31.4 62 467 74.1 69.6 
HLA9_Class 1A_A1N110 1105 54 67.9 809 70.8 67.9 
HLA9_Class 1A_5AE3.2 1068 34.4 64.9 419 84.5 64.9 
HLA9_Class 1A_3AE3.2 1049 66 68.2 853 80.2 68.2 
HLA10_Class 1A_INT2R 656 45.7 69.6 460 63.7 69.6 
HLA10_Class 1A_A1N110 1070 46.2 67.1 800 59.8 68.1 
HLA10_Class 1A_5AE3.2 698 68.9 61.7 551 84.9 61.7 
HLA10_Class 1A_3AE3.2 1093 59.7 68.8 856 76.1 68.8 
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Table 2.10: Quality and length of HLA Class 1B Sanger sequencing reads before and after 

















Primer sequence  Before Editing After Editing 
Length (bp) Quality (%) GC conc. (%) Length (bp) Quality (%) GC conc. (%) 
HLA1_Class 1B_INT2R 1203 36.2 69.3 561 77.4 69.3 
HLA1_Class 1B_3B1 1174 46.5 66.7 775 70 68,8 
HLA1_Class 1B_5BE2.2 1163 32.8 69.1 474 79.3 69.2 
HLA1_Class 1B_3BE3.2 1112 43.3 69.2 859 56 69.6 
HLA2_Class 1B_INT2R 1244 24.8 67.5 416 72.1 69 
HLA2_Class 1B_3B1 1059 24.1 67.1 386 65.5 68.9 
HLA2_Class 1B_5BE2.2 1146 19.7 66.7 387 56.3 70 
HLA2_Class 1B_3BE3.2 1021 21.3 66.8 392 55.1 67.7 
HLA3_Class 1B_INT2R 980 21.9 68.2 321 67 67 
HLA3_Class 1B_3B1 1148 30.3 65.8 457 74.4 70.5 
HLA3_Class 1B_5BE2.2 913 17.2 65.6 232 66.8 66.4 
HLA3_Class 1B_3BE3.2 1161 26.6 63.3 448 67.9 69.9 
HLA4_Class 1B_INT2R 1111 39.2 68.6 558 78.1 68.6 
HLA4_Class 1B_3B1 1157 19.4 65.7 643 34.7  65.8 
HLA4_Class 1B_5BE2.2 514 70.2 68.8 478 75.1 68.8 
HLA4_Class 1B_3BE3.2 1161 20.5 64 616 38.3 65.4 
HLA5_Class 1B_INT2R 581 78.8 68.8 560 81.4  68.6 
HLA5_Class 1B_3B1 1156 32.6 65.5 532 69.9 69.5 
HLA5_Class 1B_5BE2.2 514 69.3 69.8 477 74.2 69.8 
HLA5_Class 1B_3BE3.2 1125 31.2 66.4 434 80.6 69.8 
HLA6_Class 1B_INT2R 1200  48.8 68 625 92.8 68 
HLA6_Class 1B_3B1 1158 67.0 70.5 928 82.9 70.6 
HLA6_Class 1B_5BE2.2 1044 49.5 67.9 542 94.3 68.1 
HLA6_Class 1B_3BE3.2 1135 68.8 70.5 986 79.2 70.5 
HLA7_Class 1B_INT2R 1094 51.4 67 634 88.5 67 
HLA7_Class 1B_3B1 1125 71.7 70.4 932 85.7 70.4 
HLA7_Class 1B_5BE2.2 775 63.1 68.5 487 97.5 69 
HLA7_Class 1B_3BE3.2 1143 66.1 70.5 958 78.6 70.7 
HLA8_Class 1B_INT2R 1003 35.2 66 472 73.8 69.7 
HLA8_Class 1B_3B1 1175 53.6 69.6 909 68.9 69.5 
HLA8_Class 1B_5BE2.2 501 57.1 69.1 472 60.6 69.1 
HLA8_Class 1B_3BE3.2 1157 53.3 69.6 904 67.9 69.9 
HLA9_Class 1B_INT2R 1188 32.3 68.4 556 67.4 68.3 
HLA9_Class 1B_3B1 1016 23.6 64.9 345 69 70.1 
HLA9_Class 1B_5BE2.2 1134 26.6 67.8 480 62.3 67.9 
HLA9_Class 1B_3BE3.2 1004 23.3 65.5 326 70.9 70.9 
HLA10_Class 1B_INT2R 677 47.9 69 560 57.4 69 
HLA10_Class 1B_3B1 1113 21.3 65.7 420 54.3 68.1 
HLA10_Class 1B_5BE2.2 575 41 66.1 310 71.9 72.9 
HLA10_Class 1B_3BE3.2 972 21.4 67.2 321 64.2 70.4 
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Table 2.11: Quality and length of HLA Class 1C Sanger sequencing reads before and after 




In all three tables above it is evident that the editing/trimming of the reads is beneficial to 
their quality (Table 2.9 to 2.11). This is because the quality percentage increased in all of the 
primer reads that were trimmed except those of HLA7_Class1C (Table 2.11). This sample 
failed to sequence; some of its sequenced primer reads were too short in length making it 
impossible to edit e.g. HLA7_Class1C_INT2C, HLA7_Class 1C_BC3N1P3 and HLA7_Class 
1C_5CE2.2 (Table 2.11). 
 
 
Primer sequence  Before Editing After Editing 
Length (bp) Quality (%) GC conc. (%) Length (bp) Quality (%) GC conc. (%) 
HLA1_Class 1C_INT2C 553 62.6 70.1 435 79.3 69.7 
HLA1_Class 1C_BC3N1P3 1128 23.9 65.2 478 54.2 66.7 
HLA1_Class 1C_5CE2.2 1188 20.3 62 705 34.1 68.3 
HLA1_Class 1C_3CE3.2 1107 0,7 63.6 435 0.7 63 
HLA2_Class 1C_INT2C 456 80.7 70.6 435 84.6 70.6 
HLA2_Class 1C_BC3N1P3 908 27 65.1 300 81.7 71 
HLA2_Class 1C_5CE2.2 597 42.4 69.6 391 64.7 69.6 
HLA2_Class 1C_3CE3.2 271 0 63.2 425 1.2 66.1 
HLA3_Class 1C_INT2C 456 73.9 69.4 435 77.5  69.4 
HLA3_Class 1C_BC3N1P3 951 31.7 64.6 582 50.5 66.5 
HLA3_Class 1C_5CE2.2 401 1 58.7 188 1.6 58.5 
HLA3_Class 1C_3CE3.2 957 2.7 65.1 422 5.5 67.5 
HLA4_Class 1C_INT2C 527 71.7 70.6 432 87 70.6 
HLA4_Class 1C_BC3N1P3 941 76.6 69.8 893 80.6 69.8 
HLA4_Class 1C_5CE2.2 871 37.3 66.7 801 40.4 66.7 
HLA4_Class 1C_3CE3.2 946 10.8 69.2 853 12 69.4 
HLA5_Class 1C_INT2C 458  83.6 70.3 435 88 70.3 
HLA5_Class 1C_BC3N1P3 908 28.4 64.8 350 72.9 67.7 
HLA5_Class 1C_5CE2.2 560 45 69.8 460 51.5 69.8 
HLA5_Class 1C_3CE3.2 951 1.3 63 424 1.9 65.6 
HLA6_Class 1C_INT2C 717  53.7 68.6 542 71 68.5 
HLA6_Class 1C_BC3N1P3 941 76.8 69.9 898 80.4  70.3 
HLA6_Class 1C_5CE2.2 932 42.5 68.5 844 46.9 68.5 
HLA6_Class 1C_3CE3.2 1140 5.1 68 836 6.9 67.9 
HLA7_Class 1C_INT2C 5 - 100 5 - 0 
HLA7_Class 1C_BC3N1P3 325 0 51.1 11 0 51.1 
HLA7_Class 1C_5CE2.2 5 - 100 5 - 0 
HLA7_Class 1C_3CE3.2 210 0 57.1 58 0 57.1 
HLA8_Class 1C_INT2C 531 62.5 70.8 425 77.9 71.1 
HLA8_Class 1C_BC3N1P3 955 24.3 65.4 352 65.9 66.8 
HLA8_Class 1C_5CE2.2 560 50.2 66.2 491 56.4 66.2 
HLA8_Class 1C_3CE3.2 947 1.4 66 413 2.4 62.0 
HLA9_Class 1C_INT2C 454 74.9 69.9 434 78.3 69.6 
HLA9_Class 1C_BC3N1P3 950 32.3 63.8 553 54.8 67.3 
HLA9_Class 1C_5CE2.2 637 42.2 69.5 622 43.2 69.5 
HLA9_Class 1C_3CE3.2 955 3.7 63.7 587 5.8 66.3 
HLA10_Class 1C_INT2C 462 72.9 71.9 427 78.9 71.9 
HLA10_Class 1C_BC3N1P3 939 70.8 69.6 888 74.9 69.9 
HLA10_Class 1C_5CE2.2 480 48.7 69.5 452 48.9 69.5 
HLA10_Class 1C_3CE3.2 949 10.9 67.3 850 12.1 68 
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2.8.2 De novo Assembly 
 
Sequence assembly refers to a process where fragments (reads) of a longer DNA sequence are 
aligned and merged to reconstruct the original sequence. A reconstructed sequence is called a 
consensus sequence, which is the calculated order of most nucleotides that are found in each 
position in a sequence alignment. The de novo assembly option was used to assemble the 4 
sequencing primer reads into a consensus sequence (as seen in Figure 2.3). Steps followed in 
mapping the sequences using the de novo option into a consensus sequence are summarized 




Figure 2.3: Four reads of Sample #1 (HLA Class 1A) mapped into a consensus sequence 
using the de novo option in Geneious R8 v 8.1.8 (http://www.geneious.com). 
 
The map to reference option is used when you have a known sequence and you wish to 
compare a number of reads of the same sequence with it to locate differences. Some reads 
could not be mapped using the de novo option and therefore had to be mapped to a known 





Figure 2.4: Four reads of Sample #1 (HLA Class 1C) mapped to a known reference gene as a 
guide in constructing the consensus sequence (http://www.geneious.com). 
 
 




2.8.3 PubMed NCBI BLAST 
 
To evaluate whether the newly constructed sequences fall under the HLA Class 1 loci, the 
consensus sequences were exported into PubMed NCBI BLAST where they were aligned 
against the non redundant (NR) database of NCBI. The specificity of the consensus sequences 
was evaluated by blasting them against the database (www.ncbi.nlm.nih.gov) using the 











Figure 2.5: Image showing the evaluation specificity used in PubMed NCBI BLAST to align 
the newly constructed consensus sequences against the non redundant (NR) database of NCBI 
(www.ncbi.nlm.nih.gov). 
 
2.8.4 HLA sequence analysis 
 
Kamini Gounder, a research Scientist at the UKZN HIV Pathogenesis Program (HPP) situated 
in the Doris Duke Medical Research Institute (DDMRI) at the University of KwaZulu-Natal's 
Nelson R. Mandela School of Medicine Campus performed the HLA sequence analysis on the 
Sanger sequences. The AssignTM ATF Softwere v1.5 (Conexio Genomics, Australia) was 











3.1 Evaluation of DNA Extraction 
 
Prior to PCR amplification, the quality of all DNA samples was validated by measuring the 
DNA concentration using the Qubit 2.0 Flourometer (Table 3.1) and by DNA gel 
electrophoresis (Figure 3.1).  
 
Of the 10 samples that were evaluated, DNA yield could only be measured in 6 using the 
Qubit 2.0 Flourometer (Qubit Assay). In total, the 6 samples with a positive result had DNA 
yields mean concentration of 1.85 ng/PL (varying from 1.20 ng/PL to 3.40 ng/PL). The Qubit 
2.0 Flourometer was not able to measure DNA concentrations in samples 4, 5, 7 and 9. 
Samples that showed invalid concentrations were denoted by a (-) in Table 3.1. 
 
  Table 3.1: The DNA yield (ng /PL) in samples extracted from Dried Blood spots using the 
QIAamp® DNA Mini Kit (QIAGEN) measured using the Qubit 2.0 Fluorometer (Qubit 
Assay). 
Sample no. Original Name DNA [] ng/PL Kit used 
1 #1 3.40 QIAamp DNA Mini 
Kit 
2 #2   2.56 QIAamp DNA Mini 
Kit 
3 #3 1.49 QIAamp DNA Mini 
Kit 
4 #4  
- 
QIAamp DNA Mini 
Kit 
5 #5  
- 
QIAamp DNA Mini 
Kit 
6 #6 1.57 QIAamp DNA Mini 
Kit 
7 #7  
- 
QIAamp DNA Mini 
Kit 
8 #8 1.20 QIAamp DNA Mini 
Kit 
9 #9  
- 
QIAamp DNA Mini 
Kit 
10 #10 1.62 QIAamp DNA Mini 
Kit 
11 +ve 
(HIV –ve blood) 




One microlitre (Pl) of DNA extracted using the QIAamp® DNA Mini Kit (QIAGEN) method 
was run on a 1% agarose gel in order to determine if DNA bands could be visualized. 
Although no DNA could be measured for samples 4, 5, 7 and 9 by the Qubit 2.0 Flourometer, 
the gel image (Figure 3.1) shows that there was DNA in those samples, but in low amounts. 
The low quantity was most probably due to the low quantity of DNA that can be stored in one 




Figure 3.1: Image of an agarose gel electrophoresis showing the presence of DNA in samples 
extracted from Dried Blood Spots and the positive control. 1-10: extracted samples; +ve: 
positive control (HIV negative blood). 
 
3.2 PCR Amplification and PCR product purification 
 
Nested polymerase chain reactions (nPCR) were used to amplify HLA Class 1A, 1B and 1C 
loci using the KAPPA2GTM Robust HotStart ReadyMix 2X (KAPABIOSYSTEMS) kit. The 
PCR products for each class were separated on 1% agarose gel a with a 200bp 
O‟RangeRulerTM DNA ladder mix molecular marker. Amplification of good quality DNA is 
denoted by the presence of one distinct band (1000 bp) on the gel representing either HLA 
              1       2        3       4        5      6       7        8       9      10     +ve 
 39 
Class 1A, 1B or 1C as seen on (Figure 3.2). From the 10 samples that were amplified, 
amplification could be seen in all samples except sample 2 for HLA Class 1A, in all samples 
for HLA Class 1B, and in all except sample 7 in HLA Class 1C. 
 
 
Figure 3.2: Image of an agarose gel showing PCR amplification of HLA Class 1A, 1B and 1C 
using a sample volume of 5 μl in step 1 and 2.5 μl in step 2 and a Tm of 63°C in step 1 and 
65°C in step 2. MW: O‟RangeRulerTM  DNA Ladder molecular marker; 1-10: extracted 
samples; bp: base pairs of the product size; 1A-1C: HLA Class 1 alleles; +ve: positive control 
(HIV negative blood); -ve: negative control (water). 
PCR purification was performed on the PCR product to purify the DNA in the completed 
PCR reaction by removing the remaining dNTPs, primers, Taq, and Mg2+ ions. These 
components are all required for the PCR reaction, but post amplification, they are considered   
contaminants or impurities because they may interfere with subsequent manipulations such as 
DNA sequencing or restriction digests. Extracted samples were purified using the Pure Link 
Purification Kit (Invitrogen Life Technologies) and were thereafter subjected to 1% agarose 
gel electrophoresis to check if the samples still produced bands of the expected size (1000 
bp). 










Figure 3.3: Electrophoresis gel showing PCR amplification of HLA Class 1A, 1B and 1C 
using a sample volume of 2.5 μl in step 2 and a Tm of 63°C in step 1 and 65°C in step 2 after 
purification using the Pure Link Purification Kit (Invitrogen Life Technologies). MW: 
O‟RangeRulerTM  DNA Ladder molecular marker; 1-10: extracted samples; bp – base pairs of 
the product size; 1A-1C: HLA Class 1 alleles; +ve: positive control (HIV –ve blood); -ve: 
negative control (water). 
The extraction worked for all samples because as seen in Figure 3.3 after PCR purification all 
the PCR products still produced the expected product size for all HLA Class 1 loci. Sample 2 
which had previously failed to produce a band for HLA Class 1A now produced a band even 
though it was very faint. However, sample 7 failed to produce the expected band for HLA 
Class 1C.  
3.3 Sequence quality control 
3.3.1 Assembly 
 
The PCR products were sequenced using the ABI Prism BigDye Terminator kit v3.1 Cycle 
Sequencing Kit (USA) using 4 primers for each sample in a Sanger ABI 3100 Genetic 
Analyzer. Geneious R8 v8.1.8 was used to map the four sequences into a consensus sequence 
using the de novo assembly option (Figure 2.3). The following results were obtained: 









Table 3.2: Quality of the consensus sequences produced by mapping the four sequencing 
primer reads from Sanger sequencing using Geneious R8 v8.1.8 for each of the 10 donor 
samples under the three HLA alleles (HLA Class 1A, 1B and 1C). 
 
 
As mentioned in section 2.8.2 of the Materials and Methods, some of the primer reads could 
not be mapped into a consensus sequence using the de novo option and therefore had to be 
mapped to a known reference gene. All consensus sequences constructed with assistance of a 
known reference gene are highlighted (light grey) in the table (Table 3.2). Looking at the 





After sequence mapping 
Length (bp) Quality (%) GC conc. (%) 
 
#1 
HLA1_Class 1A 1404 91 66 
HLA1_Class 1B 1016 92.2 69.8 
HLA1_Class 1C 853 80 70.4 
 
#2 
HLA2_Class 1A 1521 76.1 66.6 
HLA2_Class 1B 1093 73.1 67.0 
HLA2_Class 1C 863 74.7 67.5 
 
#3 
HLA3_Class 1A 1258 87.4 65.5 
HLA3_Class 1B 784 80.9 65.4 
HLA3_Class 1C 863 74.4 65.1 
 
#4 
HLA4_Class 1A 1553 77.8 66.2 
HLA4_Class 1B 1065 69.4 66.3 
HLA4_Class 1C 914 96.1 69.9 
 
#5 
HLA5_Class 1A 1321 87 65.4 
HLA5_Class 1B 1060 87.1 67.3 
HLA5_Class 1C 901 72.8 65.8 
 
#6 
HLA6_Class 1A 1357 72 64.9 
HLA6_Class 1B 1119 97.9 69.1 
HLA6_Class 1C 968 94.3 69.0 
 
#7 
HLA7_Class 1A 1170 90.7 68.3 
HLA7_Class 1B 1115 94.1 69 
HLA7_Class 1C SEQUENCING FAILED 
 
#8 
HLA8_Class 1A 1273 89.9 67 
HLA8_Class 1B 1233 84.7 68.7 
HLA8_Class 1C 901 78.9 69.3 
  
#9 
HLA9_Class 1A 1088 90  67.7 
HLA9_Class 1B 1042 80.2 66.3 
HLA9_Class 1C 871 85.6 65.7 
 
#10 
HLA10_Class 1A 1219 85.2 66.2 
HLA10_Class 1B 847 70.8 66.9 
HLA10_Class 1C 885 90.0 69.6 
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quality as they all had a quality score above 70 with exception of 1 sequence (#4 HLA4_Class 
1B).  
 
3.3.2 PubMed NCBI BLAST 
 
The newly constructed sequences were exported into PubMed NCBI BLAST (Basic Local 
Alignment Search Tool). NCBI BLAST was used to align these new sequences against the 
non redundant (NR) database of NCBI. This was done in order to evaluate if the consensus 




















Table 3.3: Details of the sequences that match the GenBank non redundant (NR) database in BLAST. 




HLA1_Class 1A Homo sapiens HLA-A gene for MHC class I antigen, allele HLA-A*32:01:01 99 
Homo sapiens HLA-A gene for MHC Class I antigen, HLA-A*74:01 allele, exons 1-8 99 
HLA1_Class 1B Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*58 97 
Homo sapiens HLA-B gene for MHC class I antigen, cell line DKMS-LSL-B-691, allele HLA-B*15:new 97 
HLA1_Class 1C Homo sapiens MHC class I antigen (HLA-Cw) gene, HLA-Cw*0202var allele, exons 2, 3 and partial cds 94 
Homo sapiens HLA-C gene for MHC class I antigen, allele HLA-C*06:02:01var 95 
 
#2 
HLA2_Class 1A Homo sapiens HLA-A gene, HLA-A*0205 allele, exons 1-8 98 
Homo sapiens HLA-A gene for MHC Class I antigen, HLA-A*66:01:01 allele, exons 1-8 98 
HLA2_Class 1B Homo sapiens MHC class I antigen (HLA-B) gene, HLA-B*58:01:01 allele, complete cds 92 
Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*35:01:01:02 92 
HLA2_Class 1C Homo sapiens HLA-C gene for MHC class I antigen, allele HLA-C*12:03:01:01 95 
Homo sapiens MHC class I antigen (HLA-C) gene, HLA-C*17:01:01:03 allele, complete cds 97 
 
#3 
HLA3_Class1A Homo sapiens, HLA-A gene for MHC class I antigen, allele HLA-A*30:02:01:01 98 
Homo sapiens HLA-A gene for MHC class I antigen, allele HLA-A*03:01:01:01 97 
HLA3_Class 1B Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*18:01:01:02 93 
Homo sapiens partial HLA-B gene for MHC class I antigen, allele HLA-B*27:05:02 89 
HLA3_Class 1C Homo sapiens HLA-C gene for MHC class I antigen, cell line DKMS-LSL-560, allele HLA-C*07:new 96 
Homo sapiens isolate NT01266 MHC class I antigen (HLA-C) gene, HLA-C*07:01:01:01V allele, complete cds 95 
 
#4 
HLA4_Class 1A Homo sapiens HLA-A gene for MHC class I antigen, HLA*0201 allele, exons 1-8 99 
Homo sapiens HLA-A gene for MHC class I antigen, HLA-A*6802 allele 98 
HLA4_Class 1B Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*14:01:01 92 
Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*45:01 93 
HLA4_Class 1C Homo sapiens HLA-C gene for MHC class I antigen, HLA-C*08:02:01:02, exons 1-8 98 
Homo sapiens HLA-C gene for MHC class I antigen, allele HLA-C*05:01:01:02 95 
 
#5 
HLA5_Class 1A Homo sapiens HLA-A gene for, A*2901 allele, exons 1-8 97 
Homo sapiens HLA-A gene for MHC Class I antigen, HLA-A*66:01:01 allele, exons 1-8 96 
HLA5_Class 1B Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*44:03:01 96 
Homo sapiens HLA-C gene for MHC class I antigen, allele HLA-C*06:02:01var 96 
HLA5_Class 1C Homo sapiens HLA-C gene for MHC class I antigen, allele HLA-C*06:02:01var 96 









HLA6_Class 1A Homo sapiens HLA-A gene for MHC class I antigen, allele HLA-A*29:01:01:01 95 
Homo sapiens MHC class I antigen (HLA-A) gene, HLA-A*68:01:01V allele, complete cds 95 
HLA6_Class 1B Homo sapiens MHC class I antigen (HLA-B) gene, HLA-B*58:01:01 allele, complete cds 99 
Homo sapiens HLA-B gene for MHC class I antigen, HLA-B*5711 allele, exon 1-7 98 
HLA6_Class 1C Homo sapiens HLA-C gene for MHC class I antigen, allele HLA-C*06:02:01var 99 
Homo sapiens HLA-C gene for MHC class I antigen, allele HLA-C*06:02:01var 99 
 
#7 
HLA7_Class 1A Homo sapiens HLA-A gene for MHC class I antigen, HLA-A*01 null variant allele 99 
Homo sapiens HLA-A gene for MHC class I antigen, allele HLA-A*03:01:01:01 98 
HLA7_Class 1B Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*08:01:01 99 
Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*08:01:01 99 
HLA7_Class 1C CONSENSUS SQUENCE MAPPING FAILED 
 
#8 
HLA8_Class 1A Homo sapiens HLA-A gene for MHC class I antigen, allele HLA-A*01:01:01:01 99 
Homo sapiens MHC class I antigen (HLA-A) gene, HLA-A*36:01 allele, complete cds 98 
HLA8_Class 1B Homo sapiens MHC class I antigen (HLA-B) gene, HLA-B*15:10:01 allele, complete cds 97 
Homo sapiens HLA-B gene for MHC class I antigen, HLA-B*07:05:01 allele, exon 1-7 96 
HLA8_Class 1C Homo sapiens MHC class I antigen (HLA-C) gene, HLA-C*03:02:02 allele, complete cds 94 
Homo sapiens MHC class I antigen (HLA-C) gene, HLA-C*03:05 allele, complete cds 94 
  
#9 
HLA9_Class 1A Homo sapiens HLA-A gene for MHC class I antigen, allele HLA-A*03:01:01:01 98 
Homo sapiens MHC class I antigen (HLA-A) gene, HLA-A*74:02V allele, complete cds 97 
HLA9_Class 1B Human MHC class I antigen (HLA-B) mRNA, allele HLA-B*1522, complete cds  97 
Homo sapiens HLA-B gene, exons 2 and 3, B*1805 99 
HLA9_Class 1C Homo sapiens HLA-C gene for MHC class I antigen, complete cds, allele: HLA-C*07:02:01:05 94 
Homo sapiens HLA-C gene for MHC class I antigen, allele HLA-C*07:22 96 
 
#10 
HLA10_Class 1A Homo sapiens HLA-A gene for MHC class I antigen, allele HLA-A*23:01:01 98 
Homo sapiens HLA-A gene for MHC class I antigen, allele HLA-A*24:02:01:01 98 
HLA10_Class 1B Homo sapiens HLA-B gene for MHC class I antigen, HLA-B*4802 allele 96 
Homo sapiens HLA-B gene, exons 2 and 3, B*1805 99 
HLA10_Class 1C Homo sapiens HLA-C gene for MHC class I antigen, allele HLA-C*06:02:01var 96 
Homo sapiens MHC class I antigen (HLA-C) gene, HLA-C*17 allele, complete cds 96 
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3.3.3 HLA typing analysis 
 
The AssignTM ATF Software v1.5 (Conexio Genomics, Australia) was used for HLA typing 
analysis of the sequenced reads. This software can be used for an extensive range of 
sequencing applications and also for producing information in a unique manner for quality 
control. In this study, the software was used to assemble sequences according to the HLA 
alleles and detect variation of HLA Class 1A, 1B and 1C alleles within the reads of the 10 
sequenced samples. The following HLA results were extracted: 
 
Table 3.4: Results from the AssignTM ATF Software v1.5 (Conexio Genomics, Australia) 
used to genotype and detect variation in HLA Class 1A, 1B and 1C alleles for the 10 
sequenced samples. The numbers represent the allele and its subtype that each sequence 
matched to in the HLA Class 1 gene. 
 
Sample no. HLA-A HLA-A HLA-B HLA-B HLA-C HLA-C 
1 32:01 74:01 15 58 02:02 06:02 
2 02:05 66:01 39:01 58:01 07:01 12:03 
3 26:01 30:02 18:01 27:05 02:02 07:04 
4 02:01 68:02 14:01 45   FAILED 
5 29:01 66:01 44:03 58:02 06:02 07:01 
6 29:02 68:01 58:02 58:02 06:02 06:02 
7 01:01 03:01 08:01 08:01 FAILED 
8 01:01 68:02 15:10 81:01  FAILED 
9 03:01 74:02 08:01 15:03 02:10 07:02 
10 23:01 29:02 42:01 58:02 06:02 12/17 
 
 
The HLA gene has many possible variations; hundreds of identified versions of a specific 
gene (known as alleles) are all given a particular number to be identified by. Alleles closely 
related to eachother are grouped together as subtypes of that allele. For example looking at the 
results under the HLA-A gene for sample 1 (Table 3.4), the results show that the sequences of 
that sample matched to HLA-A*3201; subtype 01 of allele 32 of the HLA-A gene.  
 
The above results show that majority of the Sanger sequenced sequences were of good quality 
as variants could classify the major and minor HLA classification. For example, we could 
classify all samples for HLA Class 1A; for HLA Class 1B 8 out of 10 of the samples could 
identify the major and minor allele; and 50% for HLA Class 1C. Sequences that could not 
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identify the minor allele were highlighted in light grey in Table 3.4. Three of the sequences 
from HLA Class 1C could not identify any HLA typing (denoted by „FAILED’ in Table 3.4). 
 
3.3.4 PubMed NCBI BLAST result comparison with the AssignTM ATF Software v1.5 
 
The ATF classification and BLAST results were compared. This was done in order to 
evaluate if the consensus sequences fall under the HLA Class 1 loci and further see if they 
match the variant results produced in the HLA typing analysis using the AssignTM ATF 
Software v1.5 (Table 3.4).  
 
All BLASTed sequences were variants of the HLA Class 1 loci (either HLA Class 1A, 1B or 
1C). As seen in Table 3.5, the majority of the variants were common between the PubMed 
NCBI BLAST and the ATF Software v1.5. The variants for some samples however, did not 



















Table 3.5: Details of the sequences that the NCI BLAST matches were identical to the AssignTM ATF Software v1.5 classification. 




HLA1_Class 1A Homo sapiens HLA-A gene for MHC class I antigen, allele HLA-A*32:01:01 99 
Homo sapiens HLA-A gene for MHC Class I antigen, HLA-A*74:01 allele, exons 1-8 99 
HLA1_Class 1B Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*58 97 
Homo sapiens HLA-B gene for MHC class I antigen, cell line DKMS-LSL-B-691, allele HLA-B*15:new 97 
HLA1_Class 1C Homo sapiens MHC class I antigen (HLA-Cw) gene, HLA-Cw*0202var allele, exons 2, 3 and partial cds 94 
Homo sapiens HLA-C gene for MHC class I antigen, allele HLA-C*06:02:01var 95 
 
#2 
HLA2_Class 1A Homo sapiens HLA-A gene, HLA-A*0205 allele, exons 1-8 98 
Homo sapiens HLA-A gene for MHC Class I antigen, HLA-A*66:01:01 allele, exons 1-8 98 
HLA2_Class 1B Homo sapiens MHC class I antigen (HLA-B) gene, HLA-B*58:01:01 allele, complete cds 92 
- - 




HLA3_Class1A Homo sapiens, HLA-A gene for MHC class I antigen, allele HLA-A*30:02:01:01 98 
- - 
HLA3_Class 1B Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*18:01:01:02 93 
Homo sapiens partial HLA-B gene for MHC class I antigen, allele HLA-B*27:05:02 92 




HLA4_Class 1A Homo sapiens HLA-A gene for MHC class I antigen, HLA*0201 allele, exons 1-8 99 
Homo sapiens HLA-A gene for MHC class I antigen, HLA-A*6802 allele 98 
HLA4_Class 1B Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*14:01:01 92 
Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*45:01 93 
HLA4_Class 1C VARIANT ANALYSIS FAILED 
 
#5 
HLA5_Class 1A Homo sapiens HLA-A gene for, A*2901 allele, exons 1-8 97 
Homo sapiens HLA-A gene for MHC Class I antigen, HLA-A*66:01:01 allele, exons 1-8 96 
HLA5_Class 1B Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*44:03:01 96 
- - 
HLA5_Class 1C Homo sapiens HLA-C gene for MHC class I antigen, allele HLA-C*06:02:01var 96 
- - 
 HLA6_Class 1A Homo sapiens HLA-A gene for MHC class I antigen, allele HLA-A*29:01:01:01 95 
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#6 Homo sapiens MHC class I antigen (HLA-A) gene, HLA-A*68:01:01V allele, complete cds 95 
HLA6_Class 1B - - 
- - 
HLA6_Class 1C Homo sapiens HLA-C gene for MHC class I antigen, allele HLA-C*06:02:01var 99 
Homo sapiens HLA-C gene for MHC class I antigen, allele HLA-C*06:02:01var 99 
 
#7 
HLA7_Class 1A Homo sapiens HLA-A gene for MHC class I antigen, HLA-A*01 null variant allele 99 
Homo sapiens HLA-A gene for MHC class I antigen, allele HLA-A*03:01:01:01 98 
HLA7_Class 1B Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*08:01:01 99 
Homo sapiens HLA-B gene for MHC class I antigen, allele HLA-B*08:01:01 99 
HLA7_Class 1C VARIANT ANALYSIS FAILED 
 
#8 
HLA8_Class 1A Homo sapiens HLA-A gene for MHC class I antigen, allele HLA-A*01:01:01:01 99 
- - 
HLA8_Class 1B Homo sapiens MHC class I antigen (HLA-B) gene, HLA-B*15:10:01 allele, complete cds 97 
- - 
HLA8_Class 1C VARIANT ANALYSIS FAILED 
  
#9 
HLA9_Class 1A Homo sapiens HLA-A gene for MHC class I antigen, allele HLA-A*03:01:01:01 98 
Homo sapiens MHC class I antigen (HLA-A) gene, HLA-A*74:02V allele, complete cds 97 
HLA9_Class 1B -  - 
- - 




HLA10_Class 1A Homo sapiens HLA-A gene for MHC class I antigen, allele HLA-A*23:01:01 98 
- - 
HLA10_Class 1B - - 
- - 
HLA10_Class 1C Homo sapiens HLA-C gene for MHC class I antigen, allele HLA-C*06:02:01var 96 
Homo sapiens MHC class I antigen (HLA-C) gene, HLA-C*17 allele, complete cds 
                                                            or 







Logistical constraints associated with the collection and analysis of biological samples in 
community-based settings have been a significant hindrance to the development of  
biodemographic and biobehavioral research. Recent methodological developments, in 
particular the use of  dried blood spot (DBS) samples which only require a drop of whole 
blood collected on filter paper, have overcome many of these constraints (Adawaye et al., 
2013; McDade et al., 2007). They have also expanded the options for including biomarkers 
in population-based health research. Not only does this sample collection method provide a 
relatively non-invasive and painless method of obtaining blood, it also provides access to 
physiological information that would not otherwise be attainable in non-clinical settings by 
allowing accessibility to analytes that are accessible only through blood (McDade et al., 
2007). 
4.1 DNA extraction 
 
The predominant aim of this work was to find an extraction method that could isolate both 
high yield and good quality DNA from dried blood spots that can be used for host genomic 
analysis. After much evaluation (summarized in Appendix A), the QIAamp DNA Mini Kit 
method was optimized to isolate good quality DNA from DBS. The DNA yield from the 
DBS using this extraction kit was very low with a mean of 1.85ng/Pl as compared to the 
51ng/Pl (+ve) that was achieved when whole blood was used to extract the DNA using the 
same kit (Table 3.1). The low concentrations of DNA extracted from DBS could be 
explained by the small amount of blood that is used when storing the blood samples. One 
drop of blood on a DBS contains approximately 50 μl of whole blood and results in a DBS 
sample approximately 12 mm in diameter (McDade et al., 2007).  
 
There are many difficulties encountered in laboratories when extracting the maximum 
possible material from DBS. When whole blood is extracted from subjects of research, the 
blood incorparates liquid and cellular fractions, in which the cellular components are 
removed by centrifugation to yield serum or plasma in samples extracted through processes 
such as venipuncture. A difficulty faced in blood storage on DBS is that the centifugation 
step prior storage is omitted and it has been reported that when whole blood samples are 
dried on filter paper, cellular components rupture and are released into solution when blood 
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spots are reconstituted. This leads to additional extraction procedures being required for 
extraction of certain analytes to overcome the problem of inhibitors (cellular components) 
(Lakshmy, 2008), and in turn the additional extraction procedures open a doorway for 
possible contamination and also decrease DNA yield. 
 
Although low concentrations of DNA were extracted, we proceeded to determine the quality 
of the extracted samples by PCR. 
 
4.2 Amplification of the HLA Class 1A, 1B and 1C loci. 
 
In order to amplify a specific target site using any type of PCR, good quality DNA is critical 
for specificity and efficiency (Sairkar et al., 2013). Much effort was expended on optimizing 
the PCR (summarized in Appendix C). 
 
Despite the low yield of DNA that was measured in the extracted samples (Table 3.1), 
amplification of the HLA Class 1A, 1B and 1C loci through nested PCR was successful, 
which in turn confirms that the extracted DNA was sufficient to amplify HLA alleles. 
Amplification of DNA was denoted by the presence of one distinct band (1000 bp) on the 
electrophoresis gel representing either HLA Class 1A, 1B or 1C. As seen in Figure 3.2, all 
samples extracted from DBS amplified the targeted site of 1000 bp in the HLA Class 1 locus 
except sample 2 in amplification of HLA Class 1A and sample 7 in the amplification of 
HLA Class 1C.  
 
The PCR products were purified post PCR to remove all remaining dNTPs, primers, Taq, 
and Mg2+ ions in the PCR products. These components after amplification are considered to 
be contaminants as they could possibly interfere with downstream analyses such as DNA 
sequencing. Sample 2 in the amplification of HLA Class 1A after PCR purification did 
produce the expected target site of 1000 bp even though the band was not as bold as the 
bands produced by the other samples (Figure 3.3). The absence of the targeted site of this 
sample in Figure 3.2 could have been due to one of the contaminants stated above that 
probably remained in the PCR product after amplification and hindered the amplification of 
the HLA Class 1A expected site. On the other hand sample 7 in amplification of HLA Class 
1C still did not produce a band on the agarose electrophoresis gel even after the sample 
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underwent PCR purification (Figure 3.3). The absence of the expected band size in this 
sample can only be due to poor quality and/or low quantity of the sample DNA. 
 
 4.3 Sequence quality control and HLA typing analysis. 
 
 
One of the most valuable platforms that can be used to study biological systems is DNA 
sequencing; this commonly involves the use of dideoxy chain termination technology 
(Ronaghi, 2001). In this study Sanger sequencing was performed on the purified PCR 
products to sequence the HLA Class 1 loci (HLA Class 1A, 1B and 1C) from the 10 
amplified samples. The sequences attained from Sanger sequencing were analysed using 
Geneious R8 v8.1.8 and PubMed NCBI BLAST and also underwent HLA typing analysis 
using the AssignTM ATF Software v1.5 for sequence quality control purposes.  
 
4.3.1 Sequence quality control 
 
To investigate the quality of the Sanger sequenced fragments of the HLA Class 1 loci, the 
four sequences produced by sequencing for each sample (4 per allele) were mapped together 
to construct consensus sequences using the Geneious R8 v8.1.8 de novo assembly option. 
Samples that could not be mapped using the de novo option were mapped to a reference 
gene in order to obtain the consensus sequence (Table 3.3). Of all sequenced samples only 
sample 7 for HLA Class 1C failed to construct a consensus sequence. This is because the 
sequenced fragments for this HLA Class 1C sample were of poor quality (before and after 
trimming) as seen in Table 2.11. These results confirm that the DNA extracted from DBS 
was of good quality because irrespective of the low DNA concentration yields, Sanger 
sequencing was successful in majority (all except one) of the samples leading to the 
construction of consensus sequences being achievable. 
 
When the newly constructed sequences (consensus sequences) were BLASTed using 
PubMed NCBI BLAST to align these new sequences against the non redundant (NR) 
database of NCBI for quality control purposes, all the sequences fell under the HLA Class 1 
loci (Table 3.4).  
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4.3.2 HLA typing analysis 
 
It is essential to exploit the potential of the quantitative information obtained from these 
sequencing traces in order to accurately detect the variations of HLA allele sequences. In 
this study variations in the HLA allele sequences were detected through comparison of the 
HLA Class 1 alleles to a single reference sequence using the AssignTM ATF Software v1.5. 
This software is an automated program of high sophistication that is used for analysis of 
DNA sequence electropherograms to produce rapid, high throughput, quality controlled 
results from automated DNA sequencers.  
 
Results from this analysis show that host genomic analysis can be performed on DNA 
extracted from DBS as HLA major and minor allele variations were detected in majority of 
the samples. In Table 3.4 it is evident that the HLA Class 1A allele had the best sequence 
quality as  the software was able to detect variations in all 10 sequenced samples. For HLA 
Class 1B, variations were seen in all the samples except for sample 1 and sample 3. Auto 
editing is an in-built base call algorithm that is used by this program when the quality of a 
sequence peak is poor. Assign™ ATF v1.5 uses prior base calling information at a certain 
position as a guide to the most likely base. Even after editing the sequences using the 
software (auto editing), the variants matched to these samples (sample 1 and sample 3) were 
questionable. Sanger sequencing of these two samples would need to be repeated in order to 
obtain more accurate results. On the other hand  HLA Class 1C did not only have 
questionable variations (sample 3 and sample 10) but the software could not assemble some 
of the sequences and therefore variations  in sample 4, 7 and 8 could not be detected. This 
was due to the Sanger sequenced fragments being of poor quality as the software has a 
limitiation of only being able to produce results from sequences that are of good quality. The 
lengths of the 4 Sanger sequencing fragments for these samples (especially sample 7 and 
sample 8) were quite short as compared to the other samples (Table 2.11). Irrespective of the 
high quality percentange that each fragment had, the shorter the fragments are in length, the 
less specific those fragments become and, in turn, that makes it difficult to get specific 




4.3.3 PubMed NCBI BLAST result comparison with the AssignTM ATF Software v1.5 
 
The BLAST (Table 3.3) and the ATF software v1.5 classification (Table 3.4) results were 
compared. This was done in order to evaluate if the consensus sequences fall under the HLA 
Class 1 loci and further see if they match the variant results produced in the HLA typing 
analysis using the AssignTM ATF Software v1.5. As seen in Table 3.5, for majority of the 
samples the variants from the PubMed NCBI BLAST were the same as those produced in 
ATF Software v1.5. 
 
Rajatileka and associates (2013) performed a similar study to ours using DBS. In their study 
they compared the efficiency of gDNA from three different blood sources (whole blood, 
umbilical cord blood and DBS). Amongst other aims they focused on the suitability of 
newborn DBS and umbilical cord tissue for PCR and DNA sequencing. They however, used 
a next generation sequencing method known as pyrosequencing (Rajatileka et al., 2013). 
Pyrosequencing is based on the principle of sequencing by synthesis, which differs from 
Sanger sequencing in that its detection depends on the detection of pyrophosphate release in 
the incorporation of the nucleotides whereas Sanger sequencing relies on dideoxynucleotide 
chain termination (Ronaghi, 2001).  
 
Not surprisingly, and similar to our findings, the mean yield in the DNA extraction from 
DBS was lower than that of the two other blood sources.  A significant difference was 
observed between the three groups; newborn DBS had a p-value of p < 0.001 as compared 
to p < 0.01 for whole blood versus umbilical cord blood. For the purpose of validating the 
quality of the extracted DNA, a 325 bp fragment of a house keeping gene (β-actin) was 
amplified. This showed a clear specific band with the expected size. All tested samples 
produced an amplicon at the expected size (Rajatileka et al., 2013). In our study, we used 
larger fragments of 1000 bp belonging to the HLA Class 1 loci (HLA Class 1A, 1B and 1C). 
In their study, all of the amplified samples were thereafter used in the detection of two 
unrelated SNPs by pyrosequencing. While all of the samples from whole blood or umbilical 
cord produced conclusive pyrograms, 6% of rs1835740 and 14% of rs4354668 were 
unsuccessful in the detection of conclusive pyrograms for the DBS samples (Rajatileka et 
al., 2013). Their results prove that DBS has certain limitations to be used as a source of 
DNA. However, they showed that despite limitations it could be used in successful down 
stream analyses of host genes. 
 54 
In 2007, McNulty et al. assessed the use of DBS in HIV-1 drug resistance testing. They did 
so by investigating the efficiency of amplifying a 1 023 bp HIV-1 pol fragment 
(approximately the same size as the HLA Class 1 fragments used in our study) from viral 
DNA extracted from DBS collected in the field and of that collected and stored under 
conditions that were defined comparing it to the amplification efficiency of blood plasma. 
The evaluated samples collected were from two different sources. The first set was from 
Virology Quality Assessment program (VQA). They classified those samples into two 
groups (A and B), with each group consisting of a mixture of samples with a low, medium, 
or high virus load. Group A was stored at a temperature of - 30°C for 6 years and contained 
samples with resistance-associated mutations. Group B was stored at either room 
temperature (Group B1) or -70°C (Group B2) for 5 years and contained samples with wild-
type viruses. The second group of samples incorporated matched plasma and DBS samples 
from HIV-1-infected donors collected at Cameroonian blood banks. These samples were 
prepared from blood that was HIV positive. The DBS specimens had been stored for 
approximately 3 years at - 20°C, which was the same temperature our DBS samples were 
stored. The amplification was performed using an in-house reverse transcriptase (RT) nested 
PCR method (McNulty et al., 2007).  
 
Additional to this, the proviral DNA was also assessed examining similarities between pol 
sequences from paired plasma and DBS samples. Sequence analysis of HIV-1 pol was done 
in an ABI 3100 capillary sequencer and the Vector NTI program (suite 8) was used to 




The foremost findings from their study was the amplification efficiency of the large HIV pol 
fragments from DBS stored for approximately 3 years at - 20°C, suggesting that this may be 
a suitable temperature for long-term storage of DBS. For collection sites based in less-
developed areas, storing DBS at room temperature or 4°C was presented as feasible 
alternative for short-term storage (McNulty et al., 2007). A high concordance between the 
plasma and the DBS was seen as the mean similarity between the nucleotides of pol 
sequences from plasma and those of DBS ranged from 97% to 100%. Similarities between 
the amino acids were also witnessed to be very high, as they ranged from 96% to 100% 
(McNulty et al., 2007). The results mentioned above further confirm that DBS, when well 
stored, can be utilized in viral drug resistance analyses.   
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4.4 Conclusion and Future studies 
 
This study shows that, in spite of the small amount of blood that is used when storing the 
blood samples in DBS, it is possible to sequence the HLA locus directly from DBS. DBS 
can also yield valuable information such as somatic mutations in tumor tissue, emerging 
mutations in viral genomes that confer drug resistance, or evaluating the amount of 
methylation possessed by a particular CpG locus, which are all vital outcomes in the 
progression of research. In the near future, Africa Centre may apply for ethics permission to 
genotype its sample repository in order to determine the effect of host HLA on HIV-1 

























A. Protocols used in the optimisation of DNA extraction from dried blood spots 
 
A.1 DNA extraction using the Prepfiler Forensic DNA extraction Kit from cheek       
 epithelium and DBS 
 
Two DNA extraction kits, QIAamp® DNA Mini Kit (QIAGEN, Germany) and PrepFiler® 
Forensic DNA extraction Kit (Life Technologies, California) were explored to determine 
which of the two would give the best quality and yield of DNA. The two highlighted sample 
types in Table 1 (below) are the sample types that were used for the optimization of the 
Nested PCR using the PrepFiler® Forensic DNA extraction Kit. The DNA was extracted 
following the manufacturer‟s instructions. The protocol was as follows: 
 
The sample (cheek swab or DBS) was placed in a PrepFiler® Spin Tube and a mixture of 
300 μl PrepFiler® Lysis Buffer and 3 μl DTT (1.0 M) was also added to the tube making 
sure that the fluids covered the substrate. The tube was capped and vortexed using a 
VORTEX GENIE 2 (Scientific Industries) for 5 seconds, then centrifuged (Eppendorf 5418 
R centrifuge) briefly. The tube was thereafter placed in a thermal shaker and incubated at 
70°C at a speed of 900 rpm for 40 min. 
The sample was then centrifuged for 2 sec. A PrepFiler® Filter Column was inserted into a 
new 1.5ml PrepFiler® Spin Tube and the sample was carefully transferred into the filter 
column using a pipette to transfer the liquid and a pipette tip to transfer the substrate. The 
tube was then centrifuged at maximum speed (14 000 rpm) for 2 min. The filter column was 
disposed and the sample lysate was incubated at room temperature for 5 min. 15 μl of 
magnetic particles were pipetted into the tube containing the sample lysate successive to 
vortexing the PrepFiler® Magnetic Particles tube for 5 sec and inverting the tube making 
sure that no visible pellet remained at the bottom of the tube. After addition of the magnetic 
particles, the tube with the sample lysate was vortexed at a low speed (850 rpm) for 10 sec 
before being centrifuged briefly. After centrifuging, 180 μl of isopropanol was added to the 
sample lysate tube and the tube was vortexed at low speed (850 rpm) for 5 sec before being 
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briefly. The sample lysate tube was placed in a thermal shaker and was allowed to mix at 
room temperature (25°C) at a speed of 1000 rpm for 10 minutes.  
The sample DNA tube was then placed in the magnetic stand until the size of the pellet of 
magnetic particles on the back of the tube stopped increasing in size. While the sample DNA 
tube remained in the magnetic stand, a pipette was used to carefully remove and discard all 
visible liquid phase making sure that the magnetic particle pellet was not aspirated or 
disturbed.  After binding the DNA to the magnetic particles, the magnetic particles were 
washed to remove impurities and inhibitors. 600 μl Wash Buffer A was added to the DNA 
tube. The tube was removed from the magnetic stand and vortexed at high speed (10 000 
rpm) for 5 sec and thereafter centrifuged briefly for the mixture to collect at the bottom of 
the tube. The tube was placed back on the magnetic stand and was left untouched for 60 sec 
to allow the magnetic particle pellet to grow in size on the back of the tube. With the sample 
DNA tube remaining in the magnetic stand again a pipette was used to carefully remove and 
discard all visible liquid phase. The abovementioned procedure (from the addition of the 
wash buffer step to the discarding of all visible liquid phase) was repeated twice, for the 
second wash using 300 μl Wash Buffer A and 300 μl Wash Buffer B for the third wash. 
After the third wash the sample DNA tube still standing in the magnetic stand was left open 
allowing the magnetic particles-bound DNA to air-dry for 10 min. 
Thereafter an addition of 50 μl PrepFiler® Elution Buffer was added to the sample DNA 
tube prior to the tube being vortexed at maximum speed until no visible magnetic particle 
pellet could be seen. The tube was then incubated in a thermal shaker at a speed of 900 rpm 
for 5 min at 70°C. The sample DNA tube was again vortexed at maximum speed until there 
was no visible magnetic particle pellet on the side of the tube then briefly centrifuged. The 
tube was placed back on the magnetic stand and left undisturbed until the magnetic particle 
pellet on the side of the tube stopped increasing in size. All the liquid in the sample DNA 
tube (which contained the isolated genomic DNA) was pipetted into a 1.5-mL 




A.2 DNA extraction using the QIAamp® DNA Mini Kit from whole blood- generation 
of a positive control for trouble shooting 
 
In scientific research one must have a control group that gives reliable standard data to 
compare the results with. A positive control receives a treatment with a known response, so 
that this positive response can be compared to the unknown response of the treatment. For 
this research DNA extracted from whole blood was used as a positive control. The blood 
was extracted using the QIAamp® DNA Mini Kit following the manufacturer‟s instructions. 
The protocol was as follows: 
 
20 μl Proteinase K (QIAGEN) was pipetted into the bottom of a 1.5 ml microcentrifuge 
tube. An addition of 200 μl of the sample (blood) and 200 μl Buffer AL was also added to 
the microcentrifuge tube. The content of the tube were mixed by pulse-vortexing for 15 sec 
using a FINE VORTEX (FINE PCR) making sure the sample and Buffer AL were mixed 
thoroughly into a homogeneous solution to ensure efficient lysis. The tube was thereafter 
incubated in a heating block (TECHNE DRI-Block DB.2A) for 10 min at 56°C and after 
incubation the microcentrifuge was briefly centrifuged (Eppendorf 5415 R centrifuge) to 
remove drops from the inside of the lid. 200 μl of ethanol (100%) was added to the sample, 
and the tube was mixed by pulse-vortexing for 15 sec. The mixture was then transferred into 
a QIAamp Spin column placed in a 2 ml collection tube. The spin column was centrifuged at 
a speed of 6000 x g for 1 min and thereafter transferred into a clean collection tube. The spin 
column was carefully opened and 500 μl Buffer AW1 was added before the tube was 
centrifuged at 6000 x g for another 1 min. After centrifugation, the spin column was 
transferred into another clean collection tube and 500 μl Buffer AW2 was added to it. The 
spin column was then centrifuged at highest speed for 3 min. For the elimination of any 
Buffer AW2 carryover, the spin column was placed in a clean collection tube and 
centrifuged at the highest speed for 1 min, as Buffer AW2 may become an inhabitant in 
downstream applications if carried over to the eluting stage. The QIAamp Spin Column was 
then placed in a clean 1.5 ml microcentrifuge tube and 200 μl Buffer AE was added. The 
tube was incubated at room temperature for 1 min, thereafter centrifuged at 6000 x g for 1 
min. The newly extracted DNA samples were then stored at -20°C. 
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A.3 DNA extraction from epithelial tissue using the QIAamp® DNA Mini Kit  
 
The tissue (25 mg) of the tissue sample was cut into small pieces and placed in a 1.5 ml 
microcentrifuge tube. 180 μl of Buffer ATL and 20 μl Proteinase K was added to the 
microcentrifuge. The sample was then mixed by vortexing and was thereafter incubated at 
56°C in a shaking heating block until the tissue was completely lysed. The sample was 
briefly centrifuged to collect all fluid at the bottom. 200 μl Buffer AL was added to the 
sample followed by pulse-vortexing for 15 sec assuring that the Buffer AL mixes thoroughly 
with the sample before incubating in a heating block at 70°C for 10 min. Proceeding this 
step, 200 μl ethanol (100%) was added to the sample and pulse-vortexed to mix for 15 sec.  
 
The sample with its precipitate was thereafter transferred into a QIAamp Spin Column 
placed in a 2 ml collection tube and was centrifuged at 6000 x g for 1 min. The QIAamp 
Spin Column was placed in a clean 2 ml collection tube and the tube containing the filtrate 
was discarded. 500 μl Buffer AW1 was added to the QIAamp Spin Column and the spin 
column was centrifuged at 6000 x g for 1 min. The QIAamp Spin Column was again placed 
in a clean 2 ml collection tube and was topped with 500 μl Buffer AW2 and centrifuged at 
full speed for 3 min. To avoid carryover of buffer AW2 into the eluting step, the QIAamp 
Spin Column was placed in a new 2 ml collection tube and was centrifuged for 1 min at full 
speed. Thereafter the QIAamp Spin Column was placed in a clean 1.5 ml microcentrifuge 
tube and 200 μl Buffer AE was added to the microcentrifuge. The tube was incubated at 
room temperature for 1 min then centrifuged at 6000 x g for 1 min. The eluting step was 
repeated before the DNA was stored as 20 μl aliquots at -20°C. 
 
 
A.4. Sequence Assembly and Sequence Quality control 
 
A.4.1 Steps followed to construct consensus sequences using Geneious R8 v8.1.8 
 
 
Geneious R8 v8.1.8 was used to map the four sequences for Sanger sequencing into a 
consensus sequence using the De novo Assembly option. The step carried out in 





a) Launch the program Geneious. 
 
b) Import the ABI files generated by the sequencing machine to a working folder using 
the import tool 
 
c) Extract sequence using the cursor by selecting the mid-section of the sequence 
leaving out the ends, which are usually of poor quality. 
d) Click on the extract button to extract the region with good quality sequence 
 
e) Select all four extracted sequences for each sample 
 
f) Click on Align/Assemble 
 
g) Click on De novo Assemble 
 
h) Select the assembled sequence  
 
i) Right click on it and select Generate consensus 
 
j) Copy the base pairs of the consensus sequence 
 
k) Open NCBI and BLAST the sequence 
 
 
Some extracted sequences had gaps and therefore a consensus sequence could not be 
achieved. Those sequences were mapped together by doing the following:
 
 
a) Find your closest reference and copy it 
 
b) Go to FASTA on NCBI and retrieve the nucleotides of the closest reference 
 
c) Go to Sequence at the top of Geneious 
d) Select New sequence 
e) Paste sequence from FASTA and save as REFERENCE SEQUENCE 
f) Select all 4 extracted sequences PLUS the REFERENCE SEQUENCE 
g) Click on Align/Assemble 
h) Select Map to Reference 







A.4.2 Sequence quality control using NCBI BLAST 
 
  
The PubMed NCBI BLAST (Basic Local Alignment Search Tool) was used to align these 
new sequences against the non redundant (NR) database of NCBI as a sequence quality 
control. This was done in order to evaluate if the consensus sequences fall under the HLA 
Class 1 loci. The specificity of the consensus sequences was evaluated by blasting them in 


























B. General Recipes 
 
 
i. 70% Ethanol 
 
Reagent 50 ml volume (ml) 
100% Ethanol 35 
Distilled water 15 




ii. 1% Agarose Gel with ethidium bromide 
 
Reagent 100 ml volume 
Agarose 1g 
1x TBE running buffer 100 ml 
0.05 Pl/ml Ethidium bromide 30 Pl  
x The agarose powder was melted in the 1x TBE running buffer and allowed to cool 
before the ethidium bromide was added. 
 
 
To make Ethidium bromide stock solution: 
 
Reagent 1 ml volume (ml) 
Ethidium bromide 10 mg 
Di.H20 1ml 




Ethidium bromide working solution: 
 
The ethidium bromide stock solution was diluted 1:200 in di.H20 to create a 0.05mg/ml 
working solution 
 
Ethidium bromide solution: 
 
Reagent 100 ml volume (ml) 
Ethidium bromide 500 Pl 
1x TBE buffer 100ml 
x The ethidium bromide stock solution was diluted 1:200 in 1xTBE buffer to create a 




iii. 1x TBE running buffer  
 
To make up 10x TBE running buffer: 
 
Reagent 400 ml volume 
Tris-base  43.2g 
Boric acid (Merck) 22 g 
EDTA 3.72 g 
Distilled water 320 ml 
x Tris-base, boric acid and EDTA were all dissolved in 320 ml of distilled water. 
 
 
To make up 1x TBE running buffer: 
 
Reagent 1L volume 
10x TBE running buffer 100 ml 
Distilled water 900 ml 




iv. 1% agarose electrophoresis without ethidium bromide 
 
Reagent 80 ml volume 
Agarose DNase/Rnase free tablet  2 tablets 
1x TBE running buffer 80 ml 
 
x Two Agarose DNase/Rnase free tablets (BIOLINE) were melted into 80 ml of TBE 



















C. PCR Optimization 
 
Experiments were performed in two different places, the Molecular Biology laboratory in 
the School of Life Sciences, UKZN Westville Campus and the Africa Centre for Health and 
Population Studies Genomics Lab at UKZN Medical School Campus. 
 
C.1 PCR optimization performed at the School of Life Sciences Molecular Biology Lab 
 
C.1.1 DNA quantification 
 
Table 3: DNA yield (ng /PL) in samples extracted from Dried Blood spots and cheek 
epithelium using the QIAamp DNA Mini Kit and the PrepFiler® Forensic DNA extraction 
Kit. 
 




260/280 Kit used 
1 1 4,5 2,69 QIAamp DNA 
Mini Kit 
2 2 8,4 1,45 QIAamp DNA 
Mini Kit 
3 3 6,2 1,04 Forensic Kit 
(PrepFiler) 
4 4 3,6 1,66 Forensic Kit 
(PrepFiler) 
5 N(1) 2,5 2,08 QIAamp DNA 
Mini Kit 
6 10 11,2 1,48 QIAamp DNA 
Mini Kit 
7 11 5,5 1,72 QIAamp DNA 
Mini Kit 
8 12 3,2 1,86 QIAamp DNA 
Mini Kit 
9 13 3,3 1,78 QIAamp DNA 
Mini Kit 
10 14 (6) 4 1,39 QIAamp DNA 
Mini Kit 
11 15 (6) 2,6 1,52 QIAamp DNA 
Mini Kit 
12 16 (6) 1,5 19,05 QIAamp DNA 
Mini Kit 
13 17 26,5 1,9 QIAamp DNA 
Mini Kit 
14 18 5,9 1,3 QIAamp DNA 
Mini Ki 
15 9 28,1 1,97 QIAamp DNA 
Mini Kit 
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Table 4: DNA yield (ng /PL) in samples extracted from cheek epithelium cells using the 
QIAamp DNA Mini Kit. 
 
 
The tabulated DNA quantities in Table 3 and 4 were quantified through spectrophotometry 
using the Nanodrop Spectrophotometer (ND-1000) at 260/280 absorbance ratios. The 
extracted samples (Table 3) were from dried blood spots made using my own blood (15th of 
July 2014) except the two that are highlighted, which were received from Africa Centre 
Genomics Lab (made on the 7th of May 2010). The cheek epithelium samples (Table 4) 
were from anonymous donors from the School of Life Sciences given on the 6th of May 
2015. All gels done at the School of Life Sciences were made following the method 










Sample no. Sample Donor DNA (ng/uL) 260/280 Kit used 
2 Black-SA 
(Donor 1) 












21,5 2,08 QIAamp DNA 
Mini Kit 
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  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 09-12-14 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 7 Run # Optimization 
 
Reagents Volume / reaction 
(Pl) 
Water  6.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  7.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




The following table is a summary of the results seen on the electrophoresis gel that follows 








Name Phiwa Mjoli Sample DBS 















Figure 1: Image of an electrophoresis gel showing amplification of samples 1-7 using 7 Pl 




In Figure 1 it can be seen that there is non-specific amplification (PCR doublets) for both 
HLA Class 1B and 1C. The non-specific amplification could be the consequence of using 
too much DNA template in the PCR. The input sample volume (for both step 1 and step 2) 








No. Class 1B Class 1C 
1 ✗ ✗ 
2 ✓ ✗ 
3 ✓ ✗ 
4 ✗ ✗ 
5 ✗ ✗ 
6 ✗ ✗ 
7 ✗ ✗ 
MW                 1         2         3          4          5           6        7         8          9        10      11        12       13      14   
                         1B      1C       1B       1C       1B      1C       1B      1C       1B       1C       1B       1C       1B      1C   
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C1.3 Attempt of HLA amplification using 4 Pl of sample volume 
 
 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 05-01-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 7 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  9.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  4.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 








Name Phiwa Mjoli Sample DBS 
Date 11-08-14 Extraction Method QIAGEN Mini Kit 
No. Class 1B Class 1C 
1 ✗ ✗ 
2 ✓ ✗ 
3 ✗ ✗ 
4 ✓ ✗ 
5 ✓ ✗ 
6 ✓ ✗ 




Figure 2: Image of an electrophoresis gel showing amplification of samples 1-7 using 4 Pl 
sample volume using primers for HLA Class 1B and 1C alleles. 
 
 
When 4 Pl of the sample volume was used in the PCR bands of the expected size were seen 
in samples 3 to 7 for HLA Class 1B. The non-specific amplification persisted for in HLA 
Class 1C and also in samples 1 and 2 for HLA Class 1B. Since HLA Class 1C had 
consistently failed and some of the HLA Class 1B samples failed, we increased the input 
















MW                 1       2          3       4         5        6        7         8         9       10      11      12       13    14   
                         1B      1C      1B      1C     1B     1C      1B     1C     1B      1C      1B      1C     1B     1C   
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C1.4 Attempt of HLA amplification using 10 Pl of sample volume 
 
 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 03-02-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 7 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  3.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  10.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 






Name Phiwa Mjoli Sample DBS 
Date 11-08-14 Extraction Method QIAGEN Mini Kit 
No. Class 1B Class 1C 
1 ✗ ✗ 
2 ✗ ✗ 
3 ✗ ✗ 
4 ✗ ✗ 
5 ✗ ✗ 
6 ✗ ✗ 
7 ✗ ✗ 
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Figure 3: Image of an electrophoresis gel showing amplification of samples 1-7 using 10 Pl 
input sample volume and primers specific for HLA class 1B and 1C alleles. 
 
Using the volumes and concentrations of the reagents provided by Africa Centre, non-
specific amplification persisted. A single specific band for HLA Class 1B was achieved 
when the sample volume was decreased from 7 Pl to 4 Pl, keeping all the concentrations and 
volumes of the other reagents the same (Figure 2). This however did not work on all the 14 
samples amplified (amplification of sample 8 to 14 not shown). The PCR conditions that 
resulted in a specific band for HLA Class 1B resulted in non-specific amplification for HLA 
Class 1C when the sample volume was raised to 10 Pl (Figure 3) suggesting that the input 
DNA concentration is not the sole reason for PCR failure. 
  
We then attempted to optimize PCR conditions. Our first attempt was to manipulate MgCl2 
concentration. MgCl2 in PCR is a co-factor for Taq enzyme. It also helps in addition of 
correcct DNTPs complementary to the sequence in newly synthesizing strand by binding to 
the dNTPs. In short, if the MgCl2   concentration is too low, primers fail to anneal to the 
target DNA and if the concentration is too high, the base pairing becomes too strong and 
fails to denature when heated. It is therefore imperative to make sure that a balanced MgCl2 




   MW                 1         2        3         4         5         6        7        8        9       10       11      12     13      14   
                     1B      1C       1B      1C      1B       1C      1B      1C      1B      1C      1B      1C      1B      1C   
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C1.5 Attempt of HLA amplification using a concentration of 0.2 and 0.8 MgCl2 
 
 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 15-02-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 







Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Class 1B No. Class 1C 
6 (1) ✗ 6 (4) ✗ 
6 (2) ✗ 6 (5) ✗ 
6 (3) ✓ 6 (6) ✗ 
 
 




Name Phiwa Mjoli Sample DBS 
Date 11-08-14 Extraction Method QIAGEN Mini Kit 
Reagents Volume / reaction 
(Pl) 
Water  6.1 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.2 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  7.0 




  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 15-02-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  5.9 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.8 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  7.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 






No. Class 1B No. Class 1C 
6 (7) ✗ 6 (10) ✗ 
6 (8) ✗ 6 (11) ✗ 




Name Phiwa Mjoli Sample DBS 




Figure 4: Image of an electrophoresis gel showing amplification of sample 6 using a 
concentrations of 0,2 and 0,8 MgCl2 (25 mM) and 7 Pl sample input volume using primers 
specific for  HLA class 1B and 1C alleles. 
 
 
The original concentration suggested for MgCl2 was 0,4 per 20 Pl reaction. We attempted to 
optimize using lower and higher MgCl2 concentration. At a concentration of 0.2 there was 
non-specific of HLA Class 1B while HLA Class 1C did not amplify at all. Neither amplified 
at a concentration of 0.8 (Figure 4). 
 












MW                1          2           3                   4           5          6                  7           8          9                 10        11        12         





  1B 1B   1C     1C 
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C1.6 Attempt of HLA amplification using a range of annealing temperatures               
(55° to 65 °C) and different sample volumes with primers specific for HLA Class 1B 
 
 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 20-02-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  9.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  4.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55-65 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 
 













Name Phiwa Mjoli Sample DBS 
Date 11-08-14 Extraction Method QIAGEN Mini Kit 
No. Temperature Class 1B 
6 (1) 55 ✓ 
6 (4) 57 ✗ 
6 (7) 59 ✗ 
6 (10) 61 ✗ 
6 (13) 63 ✗ 
6 (16) 65 ✗ 
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  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 20-02-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  6.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  7.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55-65 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Temperature Class 1B 
6 (2) 55 ✓ 
6 (5) 57 ✗ 
6 (8) 59 ✗ 
6 (11) 61 ✗ 
6 (14) 63 ✗ 






Name Phiwa Mjoli Sample DBS 




  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 20-02-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  3.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  10.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55-65 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Temperature Class 1B 
6 (3) 55 ✗ 
6 (6) 57 ✗ 
6 (9) 59 ✗ 
6 (12) 61 ✗ 
6 (15) 63 ✗ 
6 (18) 65 ✗ 
  
DNA Extraction 
Name Phiwa Mjoli Sample DBS 
Date 11-08-14 Extraction Method QIAGEN Mini Kit 
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Figure 5: Image of an electrophoresis gel showing amplification of sample 6 with annealing 
temperatures ranging from 55° to 65 °C using 4, 7 and 10 Pl sample volumes and primers 
specific for the HLA class 1B allele. (Well 1, 4, 7, 10, 13 and 16 = 4 Pl; well 2, 5, 8, 11, 14 
and 17 = 7 Pl; well 3, 6, 9, 12, 15 and 18 = 10 Pl) 
 
 
PCR was performed under different annealing temperatures ranging from 55°C to 65°C for 
both alleles (HLA Class 1B and 1C). In conjunction with this, the sample volume was also 
varied to see which sample volume would work better with which temperature. 
 
For HLA Class 1B allele, a single specific band could be seen using both 4 Pl and 7 Pl input 
when the annealing temperature was set at 55°C and 57°C. As the temperature increased, 
non-specific amplification was evident. As previously seen, non-specific amplification was 












MW    1      2        3         4       5       6         7        8       9      10     11      12      13     14     15     16     17     18 
59  61   63 57   65   55 
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C1.7 Attempt of HLA amplification using a range of annealing temperatures (55° to 65 
°C) and different sample volumes to amplify the HLA Class 1C allele 
 
 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 09-02-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  9.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  4.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55-65 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 














Name Phiwa Mjoli Sample DBS 
Date 11-08-14 Extraction Method QIAGEN Mini Kit 
No. Temperature Class 1C 
8 (1) 55 ✗ 
8 (4) 57 ✗ 
8 (7) 59 ✗ 
8 (10) 61 ✗ 
8 (13) 63 ✗ 
8 (16) 65 ✗ 
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  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 09-02-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  6.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  7.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55-65 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Temperature Class 1C 
8 (2) 55 ✗ 
8 (5) 57 ✗ 
8 (8) 59 ✓ 
8 (11) 61 ✗ 
8 (14) 63 ✗ 





Name Phiwa Mjoli Sample DBS 




  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 09-02-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  3.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  10.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55-65 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Temperature Class 1C 
8 (3) 55 ✗ 
8 (6) 57 ✓ 
8 (9) 59 ✗ 
8 (12) 61 ✗ 
8 (15) 63 ✗ 




Name Phiwa Mjoli Sample DBS 




Figure 6: Image of an electrophoresis gel showing amplification of sample 8 with annealing 
temperature ranging from 55° to 65 °C using 4, 7 and 10 Pl sample volume and primers 
specific for HLA class 1C allele. (Well 1, 4, 7, 10, 13 and 16 = 4 Pl; well 2, 5, 8, 11, 14 and 
17 = 7 Pl; well 3, 6, 9, 12, 15 and 18 = 10 Pl) 
 
 
Non-specific amplification was seen at all annealing temperatures and volumes except 57qC 
when 10 Pl of the sample was used for amplification of the HLA Class 1C allele (Figure 6). 
 


















MW            1        2       3       4        5       6        7      8       9       10     11    12      13     14     15    16     17     18 
59  61  63 55 57  65 
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C1.8 Attempt of HLA amplification using a different PCR kit (Ex Takara) 
 
 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit Ex Takara 
Date 24-03-15 Kit Lot #  
Study HLA Typing Expiry Date  
No. of Samples 2 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  17.25 
10x Buffer 2.5 
dNTP 2.0 
Forward Primer  1.0 
Reverse Primer  1.0 
Taq 0.25 
Sample  1.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Class 1C 
7 (1) ✗ 
7 (2) ✗ 
9 (4) ✗ 
9 (5) ✗ 
  
DNA Extraction 
Name Phiwa Mjoli Sample DBS 




Figure 7: Image of an electrophoresis gel showing amplification of sample 7 and 9 using 7 




An attempt of amplifying HLA Class 1C allele using a different PCR kit (Ex Takara) was 
made to see if the problem was with the samples that had been extracted and stored or the 
reagents of the PCR kit being used. Two samples were used; one that had previously given a 
single band for HLA Class 1B (sample 7) and one that gave doublets (sample 9). As seen in 
Figure 7 (above) amplification was not a success for both samples. 
 
We were unsure whether the problem lay with the extraction kit being used to extract the 
DNA sample. We therefore decided to perform these experiments with freshly extracted 









  MW                      1           2           3            4            5           6 
Sample 7  Sample 9 
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C1.9 Attempt of HLA amplification using a fresh DBS sample extracted with the 




  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 06-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  12.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  1.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 










Name Phiwa Mjoli Sample DBS 
Date 06-04-15 Extraction Method PrepFiler Forensic Kit 
No. Class 1C 
15 (1) ✗ 




  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 06-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  11.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  2.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Class 1C 
15 (3) ✗ 




Name Phiwa Mjoli Sample DBS 




Figure 8: Image of an electrophoresis gel showing amplification of freshly extracted DNA 
(sample 15) extracted using the PrepFiler Forensic DNA extraction Kit extracted from 
stored DBS; sample volume at 1 Pl and 2 Pl using primers specific for HLA class 1C allele. 
 
 
A PrepFiler Forensic DNA extraction kit was used to extract a fresh sample of DNA from 
the stored dried blood spots performing PCR on the extracted sample the same day. No 
amplification was achieved as seen in Figure 8. 
 
It seemed, therefore, that we needed to optimize the PCR reaction. To this end, we tried 










MW                             1              2                              3            4 
                                                 1Pl                                   2Pl 
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C1.10 Attempt of HLA amplification using two different buffers (GC and 5x buffer) at 
different annealing temperatures 
 
 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 09-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 2 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  6.3 
5x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  7.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 57 - 65 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 











Name Phiwa Mjoli Sample DBS 




6 (1) 57 ✗ 
6 (2) 59 ✗ 
6 (3) 61 ✗ 
6 (4) 63 ✗ 
6 (5) 65 ✗ 
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  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 09-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 2 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  6.3 
GC Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  7.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 57- 65 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 






7 (8) 57 ✗ 
7 (9) 59 ✗ 
7 (10) 61 ✗ 
7 (11) 63 ✗ 
7 (12) 65 ✗ 
 
DNA Extraction 
Name Phiwa Mjoli Sample DBS 




Figure 9: Image of an electrophoresis gel showing amplification of sample 6 and 7 using 
two different buffers (GC and 5x buffer); sample volume at 7 Pl with annealing temperature 
ranging from 57° to 65°C for HLA Class 1C allele. (Well 1 and 8 = 57°C; well 2 and 9 = 
59°C; well 3 and 10 = 61°C; well 4 and 11 = 63°C; well 5 and 12 = 65°C) 
 
Sample that had previously given the expected product (6 and 7) were used in the PCR 
amplification using different buffers (5x buffer and GC buffer), as the GC content of the 
HLA Class 1C primers was higher than 65% (requirement for using GC buffer). Both 
buffers showed no success in amplifying the desired target at all temperatures (Figure 9). 
 
The above amplification protocol was repeated but instead of using DNA that had been 








  MW                1         2      3        4        5        6        7        8        9      10       11     12 
GC buffer 
  
5x   buffer 
  
Sample 6 Sample 7 
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C1.11 Attempt of HLA amplification using two different buffers (GC and 5x buffer) at 




  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 09-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  6.3 
5x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  7.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 
(Used the same cycles for Step 1 and 2) 
 
 
No. Class 1C 
16 (5) ✗ 





Name Phiwa Mjoli Sample DBS 





  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 09-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  6.3 
GC Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  7.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 
(Used the same cycles for Step 1 and 2) 
 
 
No. Class 1C 
16 (2) ✗ 
16 (3) ✗ 
 
DNA Extraction 
Name Phiwa Mjoli Sample DBS 
Date 09-04-15 Extraction Method QIAGEN Mini Kit 
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Figure 10: Image of an electrophoresis gel showing amplification of freshly extracted DNA 
(sample 16) comparing two different buffers (GC and 5x buffer) using a sample volume of 7 
Pl for HLA class 1C allele. 
 
A fresh DNA sample using the stored DBS was extracted with the QIAamp extraction kit 
and PCR was performed on the sample (same day) comparing two different buffers (GC and 
5x buffer) as performed in Figure 9. No amplification was accomplished for both samples as 
seen in Figure 10. 
 
We were unsure whether the problem lay with the quality of the DNA sample. We therefore 
decided to perform these experiments with fresh tissue. We extracted DNA from cheek 


















C1.12 Attempt of HLA amplification from fresh DNA extracted from cheek epithelium 
using the PrepFiler Forensic DNA extraction kit at two different sample volumes 
 
 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 20-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  12.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  1.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Class 1C 
17 (1) ✓ 






Name Phiwa Mjoli Sample Cheek epithelium 
Date 20-04-15 Extraction Method PrepFiler Forensic Kit 
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  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 20-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  11.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  2.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Class 1C 
17 (3) ✗ 
17 (4) ✗ 
DNA Extraction 
Name Phiwa Mjoli Sample Cheek epithelium  






Figure 11: Image of an electrophoresis gel showing amplification of freshly extracted DNA 
from cheek epithelium (sample 17) using the PrepFiler Forensic DNA extraction kit; 
amplified using 1 Pl and 2 Pl sample volume for HLA class 1C allele. 
 
 
A fresh sample was extracted using the PrepFiler Forensic DNA extracting kit but instead of 
extracting the DNA from dried blood spots, cheek epithelium was used instead. This was 
done to assess whether failure of PCR amplification was due to the use of DNA extracted 
from DBS. The sample volume used for the amplification was 1 Pl and 2 Pl; and the PCR 
was performed on the same day as the extraction. As seen on Figure 11, using 1 Pl sample 
volume there was amplification (but doublets). No amplification was seen when the sample 
volume was at 2 Pl. 
 
Since some form of amplification was observed when the sample volume was decreased to 1 
Pl, a stored sample was then used for amplification using sample volumes below 4 Pl to see 





     MW                          1            2                               3             4 
1Pl 2Pl 
 97 
C1.13 Attempt of HLA amplification performed on a stored extracted sample using 
sample input below 4 Pl (Ranging between 1-3 Pl) 
 
 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 21-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  12.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  1.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Class 1C 
7 (1) ✓ 







Name Phiwa Mjoli Sample DBS 
Date 11-08-14 Extraction Method QIAGEN Mini Kit 
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  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 21-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  11.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  2.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Class 1C 
7 (3) ✗ 










Name Phiwa Mjoli Sample DBS 




  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 21-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  10.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  3.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Class 1C 
7 (5) ✗ 




Name Phiwa Mjoli Sample DBS 
Date 11-08-14 Extraction Method QIAGEN Mini Kit 
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Figure 12: Image of an electrophoresis gel showing amplification of sample 7 with sample 
volume ranging from 1 to 3 Pl using primers specific for the HLA class 1C allele. 
 
A stored DNA sample (sample 7) was used to perform PCR using a decreased input sample 
volume - below 4 Pl (ranging between 1-3 Pl) as 1 Pl (Figure 11) had showed some form of 
amplification even though it was non-specific. However, using lower input volume resulted 














          MW                            1               2              3             4              5             6 
1Pl 2Pl 3Pl 
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C1.14 Attempt of HLA amplification using a freshly extracted DNA sample extracted 
using the QIAamp extraction kit from stored dried blood spots 
 
 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 23-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  12.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  1.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Class 1C 
18 (1) ✓ 






Name Phiwa Mjoli Sample DBS 
Date 23-04-15 Extraction Method QIAGEN Mini Kit 
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  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 23-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  11.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  2.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Class 1C 
18 (4) ✗ 










Name Phiwa Mjoli Sample DBS 
Date 23-04-15 Extraction Method QIAGEN Mini Kit 
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  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 23-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  10.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  3.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Class 1C 
18 (7) ✗ 










Name Phiwa Mjoli Sample DBS 




  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 23-04-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 1 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  9.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  4.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Class 1C 
18 (11) ✗ 




Name Phiwa Mjoli Sample DBS 




Figure 13: Image of an electrophoresis gel showing amplification of freshly extracted DNA 
(sample 18) with sample volumes ranging from 1 Pl to  4 Pl and using primers specific for  
the HLA class 1C allele. 
 
Since no success seen using a stored sample (Figure 12), a freshly extracted DNA sample 
extracted using the QIAamp extraction kit from the stored dried blood spots were used to 
perform PCR (same day) with sample volume ranging from 1Pl to 4Pl. PCR amplification 
was not a success as seen in Figure 13. 
  
To determine whether the problem lay in primer specificity i.e. primers specific for different 













  MW               1      2        3        4      5        6       7       8        9      10     11     12 
 2Pl  1Pl  3Pl  4Pl 
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C1.15 Attempt of HLA amplification using DNA extracted from cheek epithelium of 
individuals belonging to different ethnic groups 
 
 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 06-05-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 4 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  12.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  1.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 











Name Phiwa Mjoli Sample Cheek epithelium 
Date 06-05-15 Extraction Method QIAGEN Mini Kit 
No. Class 1C 
2 (1) ✗ 
3 (4) ✗ 
4 (7) ✗ 
5 (10) ✗ 
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  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 06-05-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 4 Run # Optimization 
 
 
Reagents Volume / reaction 
(Pl) 
Water  11.3 
10x Buffer (with MgCl2) 4.0 
Enhancer 1.0 
MgCl2 (25mM) 0.4 
dNTP 0.4 
Primer 1 (10PM) 0.4 
Primer 2 (10PM) 0.4 
KappaRobust Taq 0.1 
Sample  2.0 




Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




No. Class 1C 
2 (2) ✗ 
3 (5) ✗ 
4 (8) ✗ 





Name Phiwa Mjoli Sample Cheek epithelium 




Figure 14: Image of an electrophoresis gel showing amplification of freshly extracted DNA 
(sample 2-5 on Table 2) with sample volume ranging from 1Pl to 2Pl using primers specific 
for the HLA class 1C allele. 
 
After being able to amplify DNA with PCR using cheek epithelium even though it was non-
specific (Figure 11) it was thought that it would be interesting to see if there is a difference 
in amplification using DNA from individuals belonging to different ethnic groups. Three 
ethic groups were compared namely Indian, Coloured and Black. The “Black” group was 
further split into two, namely Black-Zimbabwe and Black-SA. 
 
The results in Figure 14 showed better amplification for the Coloured group followed by the 
Indian group; Black-Zimbabwe had a very faint band and there was no amplification for 
Black-SA. It was expected that more PCR amplification would be seen in the Black-SA 
individual as the cohort that the PCR primers being used in the troubleshooting had 
previously worked perfectly on, is based in the rural areas of a Black-SA dominant area. 
 
This suggested that either there were inhibitors in the samples or the PCR reactions required 
more optimization. It was decided to continue this work at the Africa Centre laboratory at 
the UKZN Medical School where this protocol had been developed. 
 
 
             MW            1      2       3       4       5       6      7       8      9     10    11     
Black-SA Black-ZM  Coloured Indian 
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C.2 PRC optimization performed at the Africa Centre for Health and Population 
Studies Genomics Lab (Durban). 
 
C2.1 DNA extraction 
 
DNA was extracted and quantified as stated in section 2.2 and 2.3 of Materials and methods. 
The samples used for this section of optimization are the samples shown in Table 3.1 of the 
Results section under „Evaluation of DNA Extraction‟. The 1% agarose gels were made 



































C2.2 Attempt of amplification of HLA Class 1A, 1B and 1C; comparing the efficiency 




  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust 
Date 07-07-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 





Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 63 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 
(Used the same cycles for Step 1 and Step 2) 
 
 
Reagents Volume / reaction 
(Pl) 
Mater mix for 
12 reactions (Pl) 
Water  8.3 99,6 
10x Buffer (with MgCl2) 4.0 48 
Enhancer 1.0 12 
MgCl2 0.4 4,8 
dNTP 0.4 4,8 
Primer 1 (10uM) 0.4 4,8 
Primer 2 (10uM) 0.4 4,8 
KappaRobust Taq 0.1 1,2 
Sample  5.0 - 









Name Phiwa Mjoli Sample DBS 
Date 06-07-15 Extraction Method QIAGEN Mini Kit 
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The following table is a summary of the results seen on the electrophoresis gel that follows 
(Figure 1), showing the success/failure of the attempted HLA Class 1B and HLA Class 1C 

































No. Sample ID Class 1A Class 1B Class 1C 
1 #1 ✗ ✓ ✓ 
2 #2 ✗ ✓ ✓ 
3 #3 ✓ ✓ ✓ 
4 #4 ✗ ✓ ✓ 
5 #5 ✓ ✓ ✓ 
6 #6 ✓ ✓ ✓ 
7 #7 ✓ ✓ ✓ 
8 #8 ✓ ✓ ✓ 
9 #9 ✓ ✓ ✓ 
10 #10 ✓ ✓ ✓ 
11 PC (+ve) ✓ ✓ ✓ 








(Use the same cycles for Step 1 and Step 2) 
 
 




Water  3.8 45.6 
Master Mix 10 120 
MgCl2 0.4 4.8 
Primer 1(10uM) 0.4 4.8 
Primer 2 (10uM) 0.4 4.8 
Sample  5 - 





Name Phiwa Mjoli Sample DBS 
Date 06-07-15 Extraction Method QIAGEN Mini Kit 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KappaRobust (RM) 
Date 07-07-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 12 Run # Optimization 
Thermocycling Conditions 
Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 63 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 
No. Sample ID Class 1A Class 1B Class 1C 
1 #1 ✓ ✓ ✓ 
2 #2 ✓ ✓ ✓ 
3 #3 ✓ ✓ ✓ 
4 #4 ✓ ✓ ✓ 
5 #5 ✓ ✓ ✓ 
6 #6 ✓ ✓ ✓ 
7 #7 ✓ ✓ ✗ 
8 #8 ✓ ✓ ✓ 
9 #9 ✓ ✓ ✓ 
10 #10 ✓ ✓ ✓ 
11 PC (+ve) ✓ ✓ ✓ 




Figure 1: Electrophoresis gel showing amplification of HLA Class 1A, 1B and 1C 
(following the original protocol) comparing efficiency of individual reagents compared to 
that of the ready mix (MasterMix). 
 
 
From the image above it can be seen that the ReadyMix (MasterMix) is more efficient in 
HLA amplification when compared to the individual reagents. This decision was based on 
that HLA Class 1B had less non-specific amplification using this kit and the bands produced 
were bolder compared to the individual reagents bands. 
 
The protocol used showed efficiency in amplification of the HLA class 1B allele. However, 
for HLA Class 1A the bands were present but very faint therefore optimizing was needed for 
this class. Optimizing was also needed for HLA Class 1C as there was non-specific in all the 
samples amplified. 
 
All protocol optimization were subsequently carried out using the ReadyMix (RM) due to 





     Individual reagents  ReadyMix (MasterMix) 





C2.3 Attempt of HLA amplification after repeating Step 2 of the PCR reaction for 
HLA Class 1A at a lower Tm (57qC) comparing 3 different sample volumes 
 
 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KapaRobust (RM) 
Date 08-07-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 12 Run # Optimization 
 
Thermocycling Conditions 
Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 57 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 
 
Reagents Volume / reaction Volume for 
12 reactions 
Water  7.5 97.5 
Master Mix 12.5 162.5 
Enhancer 1.0 13 
MgCl2 0.5 6.5 
Primer 1(10uM) 0.5 6.5 
Primer 2 (10uM) 0.5 6.5 
Sample  2.5 - 
Total reaction volume 25  
 
No. Sample ID Class 1A 
1 #1 ✓ 
2 #2 ✓ 
3 #3 ✓ 
4 #4 ✓ 
5 #5 ✓ 
6 #6 ✓ 
7 #7 ✓ 
8 #8 ✓ 
9 #9 ✓ 
10 #10 ✓ 
11 PC (+ve) ✓ 




Name Phiwa Mjoli Sample DBS 


















Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 57 30 sec 
72 30 sec 
72 7 min Hold 




No. Sample ID Class 1A 
1 #1 ✓ 
2 #2 ✓ 
3 #3 ✓ 
4 #4 ✓ 
5 #5 ✓ 
6 #6 ✓ 
7 #7 ✓ 
8 #8 ✓ 
9 #9 ✓ 
10 #10 ✓ 
11 PC (+ve) ✓ 
12 NTC (-ve) ✓ 
 
DNA Extraction 
Name Phiwa Mjoli Sample DBS 
Date 06-07-15 Extraction Method QIAGEN Mini Kit 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KapaRobust (RM) 
Date 08-07-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 12 Run # Optimization 
Reagents Volume / reaction Volume for 
12 reactions 
Water  5 65 
Master Mix 12.5 162.5 
Enhancer 1.0 13 
MgCl2 0.5 6.5 
Primer 1(10uM) 0.5 6.5 
Primer 2 (10uM) 0.5 6.5 
Sample  5 - 
Total reaction volume 25  
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  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KapaRobust (RM) 
Date 08-07-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples 12 Run # Optimization 
 
Thermocycling Conditions 
Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 57 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 
 
Reagents Volume / reaction Volume for 
12 reactions 
Water  2.5 32.5 
Master Mix 12.5 162.5 
Enhancer 1.0 13 
MgCl2 0.5 6.5 
Primer 1(10uM) 0.5 6.5 
Primer 2 (10uM) 0.5 6.5 
Sample  7,5 - 
Total reaction volume 25  
 
No. Sample ID Class 1A 
1 #1 ✓ 
2 #2 ✓ 
3 #3 ✓ 
4 #4 ✓ 
5 #5 ✓ 
6 #6 ✓ 
7 #7 ✗ 
8 #8 ✓ 
9 #9 ✓ 
10 #10 ✓ 
11 PC (+ve) ✓ 
12 NTC (-ve) ✗ 
 
DNA Extraction 
Name Phiwa Mjoli Sample DBS 





Figure 2: Electrophoresis gel showing amplification after repeating Step 2 of the PCR 
reaction for HLA Class 1A at a lower Tm (57qC) comparing 3 different sample volumes (2.5, 
5 and 7.5 Pl). 
 
From the above gel image (Figure 2) it can be seen that 2.5 Pl is the most efficient sample 
volume to be used compared to the other two sample volumes. This is because even though 
there is non-specific amplification, the desired region (1000 bp) is bold and is present in all 
samples (with exception of sample #6 - band is faint but present). We therefore decided to 

























C2.4 Attempt of Step 2 amplification with a temperature gradient (65qC- 55qC) for 




  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KapaRobust (RM) 
Date 16-07-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 















Reagents Volume / reaction Volume for 
9 reactions 
Water  7.5 67.5 
Master Mix 12.5 112.5 
Enhancer 1.0 9 
MgCl2 0.5 4.5 
Primer 1(10uM) 0.5 4.5 
Primer 2 (10uM) 0.5 4.5 
Sample  2.5 - 













Name Phiwa Mjoli Sample DBS 
Date 06-07-15 Extraction Method QIAGEN Mini Kit 
Thermocycling Conditions 
(Step 2) 
Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 65-55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 
No. Temperature Class 1A 
1 65.0 ✓ 
2 64.5 ✓ 
3 63.3 ✓ 
4 61.4 ✓ 
5 59.0 ✗ 
6 57.0 ✗ 
7 55.7 ✗ 

































Name Phiwa Mjoli Sample DBS 
Date 06-07-15 Extraction Method QIAGEN Mini Kit 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KapaRobust (RM) 
Date 16-07-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 
No. of Samples Positive Control Run # Optimization 
Thermocycling Conditions 
(Step 2) 
Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 65-55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 




Water  5 45 
Master Mix 12.5 112.5 
Enhancer 1.0 9 
MgCl2 0.5 4.5 
Primer 1(10uM) 0.5 4.5 
Primer 2 (10uM) 0.5 4.5 




No. Temperature Class 1A 
1 65.0 ✓ 
2 64.5 ✓ 
3 63.3 ✓ 
4 61.4 ✗ 
5 59.0 ✗ 
6 57.0 ✗ 
7 55.7 ✗ 





Figure 3: Electrophoresis gel showing Temperature Gradient (65qC- 55qC) amplification of 





Figure 4: Electrophoresis gel showing Temperature Gradient (65qC-55qC) amplification of 
HLA Class 1A using 5 Pl of sample volume. 
 
The results show that 2.5 Pl sample input and 65qC annealing temperature are the most 
favorable conditions as the boldest expected band is produced under them. We therefore 
repeated the same experiment using primers specific for HLA Class 1C.  
5 Pl   1000 bp 
                  MW              1     2       3       4       5      6       7      8 
2.5 Pl  1000 bp 
              MW              1     2       3      4       5      6       7      8 
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C2.5 Attempt of Step 2 amplification with a temperature gradient (65qC- 55qC) for 
HLA Class 1C using two different sample volumes 
 
 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KapaRobust (RM) 
Date 21-07-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 













Reagents Volume / reaction Volume for 
9 reactions 
Water  7.5 67.5 
Master Mix 12.5 112.5 
Enhancer 1.0 9 
MgCl2 0.5 4.5 
Primer 1(10uM) 0.5 4.5 
Primer 2 (10uM) 0.5 4.5 
Sample  2.5 - 








Name Phiwa Mjoli Sample DBS 
Date 06-07-15 Extraction Method QIAGEN Mini Kit 
Thermocycling Conditions 
(Step 2) 
Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 65-55 30 sec 
72 30 sec 
72 7 min Hold 




1 65.0 ✓ 
2 64.5 ✓ 
3 63.3 ✓ 
4 61.4 ✗ 
5 59.0 ✗ 
6 57.0 ✗ 
7 55.7 ✗ 







Temperature (°C) Time Cycle 
94 4 min Hold 
94 15 sec  
X 40 65-55 30 sec 
72 30 sec 
72 7 min Hold 
4 ∞ Hold 
 
 
Reagents Volume / reaction Volume for 
9 reactions 
Water  5 45 
Master Mix 12.5 112.5 
Enhancer 1.0 9 
MgCl2 0.5 4.5 
Primer 1(10uM) 0.5 4.5 
Primer 2 (10uM) 0.5 4.5 
Sample  5 - 








Name Phiwa Mjoli Sample DBS 
Date 06-07-15 Extraction Method QIAGEN Mini Kit 
  Nested PCR 
Name Phiwokuhle Mjoli Name of Kit KapaRobust (RM) 
Date 21-07-15 Kit Lot #  
Study HLA Typing Expiry Date 08/2013 




1 65 ✓ 
2 64.5 ✓ 
3 63.3 ✓ 
4 61.4 ✗ 
5 59.0 ✗ 
6 57.0 ✗ 
7 55.7 ✗ 




Figure 5: Electrophoresis gel showing Temperature Gradient (65qC-55qC) amplification of 






Figure 6: Electrophoresis gel showing Temperature Gradient (65qC-55qC) amplification of 





  1000 bp 
    MW         1       2       3     4      5      6       7     8 
2.5 Pl  
   1000 bp 
         MW           1       2        3       4      5        6      7      8 
5 Pl 
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Looking at Figure 3-6 it can be seen that the most effective annealing temperatures for both 
HLA typing Class 1A and HLA Class 1C in Step 2 range between 65qC-63.3qC (best being 
65qC) and the best sample input volume to use for these alleles is 2.5 Pl compared to 5Pl. 
 
The above observations are based on the size of the expected (target) region and how bold 
the bands are compared to each other. The conclusion was that amplifying the HLA Class 1 
loci is best performed at 63qC (Tm) using 5 Pl of sample volume for step 1 and at 65qC (Tm) 
using 2.5 Pl sample volume for step 2. The above observations were used to amplify HLA 
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